US20230321031A1 - Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof - Google Patents
Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof Download PDFInfo
- Publication number
- US20230321031A1 US20230321031A1 US18/209,954 US202318209954A US2023321031A1 US 20230321031 A1 US20230321031 A1 US 20230321031A1 US 202318209954 A US202318209954 A US 202318209954A US 2023321031 A1 US2023321031 A1 US 2023321031A1
- Authority
- US
- United States
- Prior art keywords
- powder
- nanoemulsion
- solid
- cannabinoid
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000000843 powder Substances 0.000 title claims description 120
- 241000218236 Cannabis Species 0.000 title 1
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 100
- 239000003557 cannabinoid Substances 0.000 claims abstract description 100
- 240000004308 marijuana Species 0.000 claims abstract description 51
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 46
- 239000007787 solid Substances 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims description 44
- 229940065144 cannabinoids Drugs 0.000 claims description 35
- 229920002774 Maltodextrin Polymers 0.000 claims description 33
- 239000005913 Maltodextrin Substances 0.000 claims description 33
- 229940035034 maltodextrin Drugs 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 32
- 239000002077 nanosphere Substances 0.000 claims description 29
- 238000000265 homogenisation Methods 0.000 claims description 26
- 239000008346 aqueous phase Substances 0.000 claims description 25
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 22
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 21
- 239000012071 phase Substances 0.000 claims description 21
- 229920001992 poloxamer 407 Polymers 0.000 claims description 19
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 17
- 239000002577 cryoprotective agent Substances 0.000 claims description 17
- 229960004242 dronabinol Drugs 0.000 claims description 17
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 16
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 16
- 229920001993 poloxamer 188 Polymers 0.000 claims description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 15
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 15
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 14
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 14
- 229950011318 cannabidiol Drugs 0.000 claims description 14
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000002296 dynamic light scattering Methods 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 5
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 claims description 5
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 claims description 5
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 5
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 3
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 claims description 3
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 4
- 229940044476 poloxamer 407 Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 74
- 238000009472 formulation Methods 0.000 abstract description 52
- 239000000284 extract Substances 0.000 abstract description 25
- 239000006185 dispersion Substances 0.000 abstract description 23
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 49
- 235000019198 oils Nutrition 0.000 description 49
- 239000003826 tablet Substances 0.000 description 42
- 239000000839 emulsion Substances 0.000 description 34
- 229960004793 sucrose Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 239000010460 hemp oil Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 201000006417 multiple sclerosis Diseases 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- -1 antibiotic Substances 0.000 description 13
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 11
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 11
- 229940105329 carboxymethylcellulose Drugs 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000006186 oral dosage form Substances 0.000 description 11
- 238000000527 sonication Methods 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 244000228451 Stevia rebaudiana Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 244000213578 camo Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 239000002621 endocannabinoid Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013267 controlled drug release Methods 0.000 description 2
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 2
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 229940099262 marinol Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OQJGZGAYSCWFCK-UHFFFAOYSA-N 2-[4-(furan-2-ylmethyl)-5-[[4-methyl-3-(trifluoromethyl)phenyl]methylsulfanyl]-1,2,4-triazol-3-yl]pyridine Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1CSC(N1CC=2OC=CC=2)=NN=C1C1=CC=CC=N1 OQJGZGAYSCWFCK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241001218256 Mouriri domingensis Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000416 anti-micotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940041750 cesamet Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000020235 chia seed Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940125718 cold curing agent Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229940125724 sleeping drug Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940093633 tricaprin Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Definitions
- the invention generally relates to formulations of cannabinoids, more specifically formulations as water-dispersible powders containing nanodroplets of a cannabinoid material, methods of producing thereof, as well as dosage forms and uses thereof for clinical purposes.
- Cannabinoids the active ingredients of cannabis, are produced in significantly higher amounts in resin-producing inflorescences of female cannabis plants.
- Various types of cannabis such as C. Sativa , C. Indica , C. Ruderalis may produce more than 100 different types of cannabinoids in various concentrations and proportions.
- the two main cannabinoids, the tetrahydrocannabinol (THC) and cannabidiol (CBD), have been related to a number of biologically important activities in humans, and mammals in general.
- the mammalian endocannabinoid system is a signal transduction system acting predominantly in the brain, and also in peripheral tissues.
- cannabinoid receptors have been identified so far, the most prominent are CB types 1 and 2 (CB 1 and CB 2 ).
- CB 1 and CB 2 CB 1 and CB 2 .
- the endocannabinoid system has been implicated in maintenance of the normal mammalian homeostasis, including systems of movement control, pain, appetite, memory, immunity and inflammation, and others. This explains the high therapeutic potential of cannabis-based medicines, and exogenous cannabinoids, and their broad clinical applications.
- Beneficial effects of cannabis have been revealed in a number of clinical conditions such as pain (pain in cancer, fibromyalgia related and neuropathic pain), inflammatory diseases (e.g. inflammatory bowel diseases, Crohn's disease, ulcerative colitis), posttraumatic stress disorder (PTSD), loss of appetite/anorexia, sleep disorders, multiple sclerosis (MS), epilepsy, autism, schizophrenia, and other disorders.
- pain pain in cancer, fibromyalgia related and neuropathic pain
- inflammatory diseases e.g. inflammatory bowel diseases, Crohn's disease, ulcerative colitis
- PTSD posttraumatic stress disorder
- MS multiple sclerosis
- epilepsy autism
- schizophrenia schizophrenia, and other disorders.
- analgesic, antiemetic, antioxidative, neuroprotective and anti-inflammatory effects are only a few among various activities attributed to the two most studied cannabinoids THC and CBD.
- Marinol capsules containing dronabinol, a synthetic ⁇ 9 -THC isoform, in sesame oil, have been approved in a number of countries as an antiemetic for cancer patients under chemotherapy and patients with AIDS.
- Cesamet capsules with nabilone, a synthetic THC analog have been approved as a Marinol substitute.
- More recent formulations Namisol tablets with pure THC and Arvisol tablets with pure CBD approved for Alzheimer's disease and chronic neural pain, and Sativex (nabiximols), an oral spray containing THC and CBD, for multiple sclerosis.
- cannabinoids One general problem with pharmaceutical formulations of cannabinoids ensues from their highly lipophilic nature. Most of the existing cannabinoid- and cannabis-based formulations use relatively high concentrations of oil to achieve therapeutically effective concentrations of actives. Other major disadvantages, related to the afore-mentioned, is revealed in their poor bioavailability and high patient variability, as well as relatively short product life due to formulation instability.
- the present invention provides solid formulations of cannabinoids or cannabis-based extracts in a form of readily water-dispersible fine powders or tablets containing oil droplets of predetermined sizes.
- One of the distinctive features of formulations of the invention is in their ability to recover, upon contact with water or a water-based environment, the same oil droplets, in substantially the same size.
- the inventors have developed a solid-based delivery system derivable from an initial fine-tuned nanoemulsion that is tailored to contain lipophilic nanodroplets of a desired size.
- the conversion of the nanoemulsion to the solid-based delivery system, i.e., powder maintains the integrity, content and size of the nanodroplets. Their integrity, content and size are further maintained when the solid-based delivery system is re-dispersed in water or when it comes into contact therewith.
- the formulations should comprise at least one cryoprotectant such as sucrose, trehalose, or mannitol, at least one surfactant as ammonium glycyrrhizinate, pluronic F-127, F68, and optionally at least one carbohydrate such as maltodextrin and carboxymethyl cellulose (CMC).
- cryoprotectant such as sucrose, trehalose, or mannitol
- surfactant as ammonium glycyrrhizinate
- pluronic F-127, F68 e.glycyrrhizinate
- carbohydrate such as maltodextrin and carboxymethyl cellulose (CMC).
- particle size can be further modulated or controlled by selecting material combinations or by certain steps in the method of production of formulations of the invention, such that the size of the nanodroplets may be pre-tailored to be within 50 and 900 nm. This may be achieved, for example, by employing steps of lyophilization, homogenization and/or sonication to achieve the powder forms.
- the presently described solid formulations may be loaded with an large amounts of the lipophilic/oil fraction; amounts that under some embodiments can be as high as 75% of the powder form or up to as much as 50% of the powder form (w/w). This feature is particularly important in view of the highly lipophilic nature of cannabinoids, their poor water-solubility and lability to thermal and photolytic degradation and oxidation, all making the design of cannabinoid formulations particularly challenging.
- Liquid pharmaceutical formulations of cannabinoids are not always achievable. Despite the expected advantages (e.g., easy to swallow, uniform delivery and rapid onset), such formulations usually require relatively large volumes of solvents. With solid formulations, meant to overcome this disadvantage, dissolution of cannabinoids imposes a critical problem.
- the feature of high loading with respect to the lipophilic/oil fraction containing the cannabinoids, this without alcohols or other water-miscible solvents, or without any solubilizing agents makes the cannabinoid formulations of the invention especially advantageous in terms delivery of therapeutically effectives doses of actives.
- the capability to modify or control loading of the oil fraction would be one way to control doses of actives in a formulation of a certain type, being it a cannabinoid-based (e.g., THC and/or CBD) or a cannabis-based formulation.
- a cannabinoid-based e.g., THC and/or CBD
- this provides a standardized pharmaceutical raw material with known concentrations of cannabis (unlike when dealing with inflorescences).
- the invention provides a solid homogeneous formulation of highly hydrophobic actives, in an administrable form, with relatively high load of actives, while being exempt from co-solvents such as alcohols.
- the formulations of the invention while being solid and compact are at the same time easily dispersible in water, with the actives retaining their properties in the oil phase, providing increased stability.
- formulations of the invention remained stable for a period of 12 months or more.
- the powder formulations of the invention can be further solidified or compressed into a solid form, such as a tablet and films, without affecting their stability and functionality.
- the present invention further provides a method for producing such powder formulations.
- the methods of the invention have been presently exemplified using hemp oil and cannabis oils.
- Methods of the invention can be adapted to include one or more specific cannabinoids, synthetic or isolated from natural sources, and also complete or fractionated extracts of cannabis plants, in various proportions and combinations.
- Another important objective of formulations of the invention is to maximize the potential of an increased bioavailability, especially for oral dosage forms. Achieving an effective oral delivery is essential for any successful therapeutic strategy, in terms of maximizing therapeutic effects, achieving stable and predictable drug plasma levels and pharmaco-dynamic effects, and as a consequence, increased patient compliance.
- Cannabinoids have been proven particularly difficult to deal with due to their limited solubility in plasma and consequently limited bioavailability, and significant first pass effect. Thus there is still an unmet need for effective oral cannabinoid- and cannabis-based formulations, particularly in powder oral forms.
- the cannabinoid formulations of the invention due to their particular physical properties, being lipo-nanospheres of a particular particle (droplets) size, have a potential to overcome these limitations, in terms of increased dissolution or dispersion of actives, increased bioavailability and protection of actives from P-gp metabolism.
- formulations of the invention can be easily adapted to oral dosage forms such as tablets and sublingual tablets or capsules with various controlled doses of actives, i.e., cannabinoids or cannabis extracts.
- Such preparations can comprise additional therapeutic agents tailored for specific therapeutic indications which could benefit from cannabinoids and cannabis-based medicines. They can further comprise minerals, antioxidants, nutrients and vitamins in forms consumed directly with food.
- the powder formulations can be further adapted for other administration methods, such as inhalation methods and devices, by using suitable pharmaceutical excipients.
- suitable pharmaceutical excipients such as inhalation methods and devices.
- the formulations of the invention can be further adapted as creams and aqueous dispersions for topical and transdermal administrations or generally as depositories.
- formulations and dosage forms can be further improved by the addition of permeation enhancers to increase bioavailability, and controlled release agents in the form of a matrix or a coating using know in the art methods.
- FIG. 1 A-B shows Cryo TEM analysis of the formulation of the invention for ( FIG. 1 A ) the nanoemulsion (10% in water) with droplet size in the range of 80-120 nm; and ( FIG. 1 B ) the dispersed powder (1% in water) with droplet size in the range of 70-130 nm (see Example 1).
- FIG. 2 shows the effect of surfactant concentration (between 3.2-7.7% w/w) on droplet size of a formulation of the invention (in the range of 251-450 nm) (see Example 5).
- FIG. 3 shows the effect of sonication time (between 5 to 60 min) on the droplet size of the formulation (in the range of 60-220 nm) (see Example 6).
- FIG. 4 shows the effect of high pressure homogenization (between 1-6 runs) on droplet size of the formulation (in the range of 167-198 nm) (see Example 7).
- FIG. 5 shows the effect of hemp oil concentration (between 19-50% w/w) on droplets size of the nanoemulsion (dashed) and dispersed powder (solid) with droplets in the range of 130-190 nm (see Example 8).
- HOP hemp oil powder
- MS magnesium stearate
- G Glycine
- PVP 40,000
- FIG. 7 shows experiments mimicking sublingual dissolution of the HOP and Centrum tablets (see Example 12)
- FIG. 8 shows tablet weight vs. disintegration time comparing the HOP (grey squares) and Centrum pill (black dots) tablets.
- the invention first provides a water-dispersible powder comprising lipophilic nanospheres (or nanodroplets or lipo-nanospheres) having an averaged size between 50 and 900 nm, the nanospheres having an adsorbed layer of at least one solid surfactant and containing a cannabinoid material, wherein the at least one solid surfactant is selected from ammonium glycyrrhizinate, pluronic F-127 and pluronic F68; the powder further comprising at least one solid cryoprotectant selected from sucrose, trehalose and mannitol, and optionally at least one solid carbohydrate selected from maltodextrin and carboxymethyl cellulose (CMC); wherein the nanospheres structure and size is substantially maintained upon dissolution in a water containing environment.
- lipophilic nanospheres or nanodroplets or lipo-nanospheres having an averaged size between 50 and 900 nm
- the nanospheres having an adsorbed layer of at least one solid surfactant
- pluronic F-127 and pluronic F-68 are BASF ethylene oxide/propylene oxide block copolymers of known structures and molecular weights.
- the powder of the invention is a solid form comprising a plurality of material nanospheres, each having a shell of at least one surfactant and containing the cannabinoid material.
- lipophilic nanospheres . . . having an adsorbed layer of at least one solid surfactant and containing a cannabinoid material refers to the fact that these nanospheres, used interchangeably with nanodroplets or lipo-nanospheres, are material entities that are spherical or substantially spherical in shape, contain a cannabinoid material and surface-adsorbed by a film of the at least one surfactant.
- the nanospheres may have an adsorbed layer consisting of the at least one surfactant or have an adsorbed layer that comprises at least one surfactant as well as an amount of the other material components present in the powder.
- the powder of the invention is derivable from a nanoemulsion that comprises a plurality of oil nanodroplets comprised of the cannabinoid material.
- the nanodroplets are of a size between 50 and 900 nm that is conserved in the solid powder.
- the integrity, content and size of the nanodroplets is maintained.
- nanodroplets integrity, content and size are further conserved when the solid-based delivery system is re-dispersed in water or when it comes into contact therewith.
- the nanodroplets integrity, content and size are unaffected by acidic conditions and therefore powders of the invention may be delivered in vivo, ensuring safe and effective delivery of the nanodroplets cargo at pH values between 1 and 7.
- powders with pre-tailored populations of oil droplets(nanospheres) of narrow size distributions may be prepared, to meet the target uses.
- the powders of the invention may comprise nanospheres of a size between 50 and 900 nm, or between 50 and 100 nm, or between 50 and 150 nm, or between 50 and 200 nm, or between 50 and 250 nm, or between 50 and 300 nm, or between 50 and 350 nm, or between 50 and 400 nm, or between 50 and 450 nm, or between 50 and 500 nm, or between 50 and 550 nm, or between 50 and 600 nm, or between 50 and 650 nm, or between 50 and 700 nm, or between 50 and 750 nm, or between 50 and 800 nm, or between 50 and 850 nm, or between 100 and 150 nm, or between 100 and 200
- the nanospheres have an averaged diameter of between 200 and 400 nm, or between 250 and 400 nm, or between 250 and 350 nm, or between 200 and 500 nm, or between 250 and 500 nm.
- the nanospheres have an averaged diameter of between 100 and 400 nm, or between 150 and 400 nm, or between 150 and 350 nm, or between 100 and 500 nm, or between 150 and 500 nm.
- the nanospheres have an averaged diameter of between 200 and 250 nm, or between 250 and 300 nm, or between 300 and 350 nm, or between 350 and 400 nm, or between 400 and 450 nm or between 450 and 500 nm.
- the nanospheres have an averaged diameter of between 200 and 210 nm, or between 210 and 220 nm, or between 220 and 230 nm, or between 230 and 240 nm, or between 240 and 250 nm, or between 250 and 260 nm, or between 260 and 270 nm, or between 270 and 280 nm, or between 280 and 290 nm, or between 290 and 300 nm.
- the nanospheres have an averaged diameter of between 210 and 310 nm, or between 220 and 320 nm, or between 230 and 330 nm, or between 240 and 340 nm, or between 250 and 350 nm, or between 260 and 360 nm, or between 270 and 370 nm, or between 280 and 380 nm, or between 290 and 390 nm, or between 300 and 400 nm.
- the powder of the invention upon dispersion in water, produces nanodroplets (spheres in the submicron scale) with an average size of between 50 and 900 nm, being an averaged size that is substantially identical.
- an increase or decrease in the size of the nanodroplets may be achieved upon dispersion.
- a difference between the nanodroplets in the initial emulsion and the those in the dispersed medium may be tailored to about ⁇ 20-30 nm for emulsions with 10% dispersed fraction of the oil droplets and no higher than ⁇ 100 nm for emulsions with 30% dispersed fractions.
- the exact range can vary as indicated above, e.g., between 50-100 nm, 100-200 nm, 200-300 nm, 300-400 nm, 400-500 nm, and in certain embodiments more than 500 nm.
- the exact droplets size and size distribution can be controlled by changing the composition of the emulsion or features of the emulsion, such as phase fraction and surfactant concentrations and by changing the preparation parameters such as pressure and number of cycles in case high pressure homogenizer is used for preparing the emulsions.
- nanospheres with a substantially same average size supports the fact that the nanospheres present in the powder conserve their size upon reconstitution of the powder in water or a water containing environment.
- the size is said to be “substantially the same”, namely the average size is identical to that in the powder or is within ⁇ 10% of the original size.
- the powder of the invention comprises sucrose, trehalose or mannitol, a cannabinoid material and further ammonium glycyrrhizinate and maltodextrin.
- the powder comprises pluronic F-127 or pluronic F68, a cannabinoid material and further sucrose and maltodextrin.
- the powder comprises sucrose, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- the powder comprises ammonium glycyrrhizinate, Maltodextrin, sucrose and a cannabinoid material.
- the powder comprises mannitol, ammonium glycyrrhizinate, maltodextrin and a cannabinoid material.
- the powder comprises mannitol, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, ammonium glycyrrhizinate, maltodextrin and a cannabinoid material.
- the powder comprises mannitol, pluronic F-127, maltodextrin and a cannabinoid material.
- the powder comprises mannitol, pluronic F-127, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, pluronic F-127, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, pluronic F-127, maltodextrin and a cannabinoid material.
- the powder comprises mannitol, pluronic F-68, maltodextrin and a cannabinoid material.
- the powder comprises mannitol, pluronic F-68, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, pluronic F-68, maltodextrin, CMC and a cannabinoid material.
- the powder comprises trehalose, pluronic F-68, maltodextrin and a cannabinoid material.
- the at least one surfactant may be comprised in the powder in an amount ranging between about 1 and 10% (w/w), more specifically as high as 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% (w/w) surfactant.
- the amount of the surfactant may be less than 1% or more than 10%.
- the amount of the at least one carbohydrate in the powder may be between 20 and 40% (w/w).
- the amount of CMC, where used, may be about between 0.1 and 3% (w/w). In some embodiments, the mount of CMC is about 1%.
- powders of the invention comprise an amount of the cannabinoid material in the range of about 10-50% (w/w), more specifically in the range of 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50% (w/w), or more.
- the cannabinoid material may be a synthetic or natural cannabinoid(s), a cannabis extract(s) or a fraction thereof.
- this term denotes the entire class of chemical compounds, cannabinoid/cannabinoid agonists/cannabinoid-related compounds, acting with various affinities on the endogenous cannabinoid receptors (CB 1 and CB 2 ).
- This group of ligands include the endocannabinoids (produced naturally by humans and animals), phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially).
- cannabinoid material further refers to the classical cannabinoids originating from or mimicking the natural cannabinoids in a cannabis plant.
- the main classes of the classical cannabinoids are shown in Table 1 below.
- the powders of the invention comprise nanospheres with one or more cannabinoids belonging to one or more of the above classes.
- the powders of the invention comprise nanospheres with extract cannabis oils.
- Extract cannabis oils can be full extracts (FECO), one example of those is Rick Simpson Oil (RSO), or extracts enriched in specific cannabinoids (THC or CBD).
- FECO full extracts
- RSO Rick Simpson Oil
- THC or CBD extracts enriched in specific cannabinoids
- Such extract oils can be obtained from C. Sativa , C. Indica , C. Ruderalis strains, more potent preparations are obtained from female flowers.
- the nanoemulsion comprising the at least one cannabinoid material comprises (a) an aqueous formulation comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein; and (b) an oil comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- the method comprises:
- the method comprises preparing an aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined above.
- the method comprises preparing an oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- the method comprises:
- nanoemulsion obtained, the powder formed, and the emulsion obtained upon dispersion of the powder in water produces nanospheres (nanodroplets) of substantially the same size, being a submicron size, and an average size as recited above.
- the step of preparing the emulsion comprises high pressure homogenization of both phases for at least 1 to 10 runs, more specifically for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 runs or more.
- the step of preparing the emulsion can involve sonication for at least about 5-60 min, more specifically for at least about 5-10 min, 10-20 min, 20-30 min, 30-40 min, 40-50 min, 50-60 min or more.
- the step of preparing the aqueous phase is carried out at room temperature.
- the powders of the invention can be further solidified or compressed into solid forms.
- the solid forms can be tablets, capsules or films, as presently exemplified.
- powders of the invention retain their physical and chemical properties at room temperature for a period of at least 12 months or more, i.e., the powders of the invention remain stable for at least about 6 months, 9 months, 12 months or more at room temperature, they are easily convertible into pharmaceutical preparations of a variety of forms, suitable for a variety of administration modes and for use in a variety of medicinal applications.
- compositions may be solid compositions or may be reconstituted compositions, in which case—in addition to the water-dispersible powders may further comprise a pharmaceutically acceptable buffer or liquid carrier.
- the pharmaceutical compositions of the invention comprise powders with synthetic or natural cannabinoids, cannabinoid combinations, cannabis extracts or fractions thereof.
- the composition of the invention comprise a synthetic or a natural cannabinoid which is one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CB G), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), and a derivative, a precursor or an acid-form of any of the aforementioned.
- THC tetrahydrocannabinol
- CBD cannabidiol
- CBD cannabinol
- CB G cannabigerol
- CBC cannabichromene
- CBD cannabicyclol
- CBV cann
- cannabinoids cannabigerol-type compounds and differ mainly in the way this precursor is cyclized.
- the classical cannabinoids are derived from their respective 2-carboxylic acids (2-COOH, also denoted with —A) by decarboxylation (catalyzed by heat, light, or alkaline conditions).
- 2-carboxylic acids (2-COOH, also denoted with —A)
- decarboxylation catalyzed by heat, light, or alkaline conditions.
- THC-A and CBD-A tetrahydrocannabinol and cannabidiol acid precursors
- the composition of the invention can comprise a full or partial extract in the form of a cannabis oil obtained from C. Sativa , C. Indica , C. Ruderalis strains, flowers and other parts.
- Oil extracts can be made using linseed oil, hemp oil, sesame oil, olive oil (the most common example), castor oil, chia seed oil, cotton oil, corn oil, coconut oil, sunflower oil, soybean oil, canola oil, etc.
- the linseed, castor and sesame oils are particularly advantageous as they contain alpha-linolenic acid, an essential nutrient.
- cannabis-based compositions are in their added content of terpenes, sesquiterpenes, carotenes, flavonoids, being present in various combinations and proportions, and which contribute to absorption, activity and further to flavor-, odor-, and color-imparting properties, in the sense of being more user-friendly.
- compositions of the invention can comprise additional therapeutic agents. This feature is explained in detail below.
- applicable agents e.g., antibiotic, anti-epileptic, anti-spastic, anti-inflammatory, analgesic and antipsychotic and others.
- compositions of the invention can further comprise antioxidants, minerals, nutrients, vitamins or combinations thereof, which can be consumed together with food or as food supplements.
- compositions of the invention are particularly advantageous as many vitamins, such as vitamin E, have the same problems of solubility and bioavailability as the cannabinoids.
- compositions of the invention comprise up to about 75%, 60%, or 50% (w/w) actives, more specifically up to 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% (w/w) actives, and in certain embodiments even more.
- active refers to a cannabis oil or an oil form of the cannabinoid material.
- compositions of the invention can further comprise antioxidants, absorption enhancers, color- and flavor-imparting agents, preservatives, stabilizers, salts, in various combinations.
- Various sweeteners, taste modifiers, antioxidants, preservatives which are well known in the art include taste modifiers such as artificial sweeteners, flavorings as strawberry and peppermint oil, for example, plant sweeteners, sugars, honey, Stevia, steviol, glycosides, citrate, acids, menthol, anise, eucalyptus oil, fennel, natural antimicrobial substances and natural antioxidant (e.g.
- extracts of murta, oregano, rosemary, borage antioxidants such as vitamins E (tocopherol) and C and their derivatives, butylated hydroxyanisole (BHA), butylated hydroxytolune (BHT) recognized as GRAS, and sulfides; any sweetener allowed for oral administration such as sugar, glucose, sucralose, glycine, cyclamate, sucrose, saccharin, fructose, maltose, stevia extract, sodium saccharine; salts such as NaCl, NaHCO 3 , Na 2 CO 3 , citrate, and others.
- antioxidants such as vitamins E (tocopherol) and C and their derivatives, butylated hydroxyanisole (BHA), butylated hydroxytolune (BHT) recognized as GRAS, and sulfides
- BHA butylated hydroxyanisole
- BHT butylated hydroxytolune
- any sweetener allowed for oral administration such as sugar, glucose, sucralose
- additives can be used, such as various solidifiers and viscosity modifiers, in various doses such as stearic acid, ascorbyle palmitate, palmitic acid, or hexadecanoic acid, polymers, magnesium stearate, cetyl alcohol, cetostearyl alcohols, stearyl alcohol; and specific viscosity enhancers such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), sodium alginate, PG alginate, polyacrylic acids such as Carbopol, mucoadhesive polymers, Carbophils, celluloses, cellulose-ethers such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hyaluronic acid (HA), alginic acid, xanthan gum, pectins, carrageenan.
- PVA polyvinyl alcohol
- PVP polyvinylpyrrolidone
- compositions of the invention can further comprise a controlled release agent.
- a controlled release agent This feature is explained in detail further below, in the context of oral dosage forms. In general terms, this feature here encompasses controlled and modifying release agents provided in the form of matrix and/or coating.
- compositions of the invention are adaptable for any type of administration, as known in the medicinal or veterinary sciences.
- Powders as well as reconstituted formulations may be configured or engineered or adapted or selected or used for topical administration, enteral administration (e.g., including all systemic administration routes involving administration via the gastrointestinal tract), or parenteral administration (e.g., including all systemic administration routes, not involving administration via the gastrointestinal tract).
- Non-limiting administration routes effective for administration or powders or reconstituted formulations of the invention include oral, sublingual, mucosal, aerosol, inhalation, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal and vaginal administrations.
- dosage forms for oral or sublingual administrations comprising the previously described compositions and powders.
- the oral dosage forms of the invention can be generally characterized as comprising at least one synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- the oral dosage forms of the invention can comprise at least one synthetic or natural cannabinoid which is THC, CBD, CBN, CBG, CBC, CBL, CBV, THCV, CBDV, CBCV, CBGV, CBGM, as a derivative, a precursor or an acid-form.
- oral dosage forms of the invention can comprise a cannabis extract or a fraction obtained from a strain C. Sativa , C. Indica , C. Ruderalis or a combination thereof.
- oral dosage forms of the invention can further comprise additional therapeutic agents, minerals, nutrients, vitamins in various concentrations and combinations.
- controlled release refers to a property or a modification enabling to achieve time dependent release, sustained release, prolonged release and also pulse release, i.e., delayed release of the drug.
- the term further relates to gastro-resistance, i.e., a property or a modification enabling to achieve pH-controlled drug release, gastrointestinal targeting, colon delivery, protection of acid-sensitive actives, protection of gastric mucosa from aggressive actives. In this sense, gastro-resistance is also targeted drug release.
- Gastro-resistant coatings and modifications are also known to improve storage stability.
- Improved gastro-resistance and/or controlled release can be achieved by modification of and/or coating using various pharmacological technologies, such as use of poly(meth)acrylates or layering.
- pharmacological technologies such as use of poly(meth)acrylates or layering.
- a well know example of poly(meth)acrylate coating which has been widely used in the pharmacological industry to achieve targeted and controlled drug release is EUDRAGIT®.
- Another important feature of poly(meth)acrylate coating is protection from external influences (moisture) or taste/odor masking to increase patient compliance.
- Certain solid oils can be added to facilitate controlled release, such as mono-, di- and triglyceride oils, in general, and trilaurin, tricaprin, tripalmitin, trimyristin, glyceryl, hydrogenated palm oil distearate, hydrogenated castor oil, hydrogenated vegetable oil, in particular.
- oral dosage forms of the invention can comprise matrix modifying/controlled release materials, which include, although not limited to, glycerides, waxes, fatty acids, methyl acrylate, methylmethacrylate, ethyl cellulose, poly(vinyl alcohol) (PVA), poly(vinyl pyrrolidone) (PVP), starch, polysaccharides, and others.
- matrix modifying/controlled release materials include, although not limited to, glycerides, waxes, fatty acids, methyl acrylate, methylmethacrylate, ethyl cellulose, poly(vinyl alcohol) (PVA), poly(vinyl pyrrolidone) (PVP), starch, polysaccharides, and others.
- oral dosage forms of the invention can be coated with hydroxypropyl methylcellulose, poly(meth)acrylates, methyl acrylate-methacrylic acid copolymers, cellulose acetate, polyvinyl acetate phthalate, and other types of coatings.
- the oral dosage forms of the invention can be provided in the form of a tablet or a capsule, both being the most popular and convenient methods of oral drug delivery.
- a capsule can be coated with a gastro-resistant coating using GRAS-based materials.
- these dosage forms can use a secondary package, such as a blister (PVC/PVDC—Alufoil), a bottle, an aluminum pouch, others.
- a secondary package such as a blister (PVC/PVDC—Alufoil), a bottle, an aluminum pouch, others.
- the above described powders, composition and dosage form of the invention can be applied for the treatment and alleviation of a number of disease and medical conditions, specifically those wherein beneficial effects of cannabinoids or cannabis-based medicines have been previously demonstrated.
- the invention provides a range of therapeutic methods for treating diseases or medical conditions related to beneficial effects of cannabinoids or cannabis, by application of presently described powders, pharmaceutical compositions or dosage forms.
- the therapeutic methods of the invention can be applied to a wide range of human conditions, including inflammatory, neurological, psychiatric disorders, malignancies and further immune, metabolic disorders, nutritional deficiencies, infectious diseases, and types of gastrointestinal disorders, cardiovascular disorders, and various types of pain, including chronic and neuropathic pain.
- a “therapeutically effective amount” (also a pharmacologically or a pharmaceutically or a physiologically effective amount) denotes an amount of the cannabinoid material needed to achieve the anticipated or desired physiological response. The precise amount is dependent on numerous factors, e.g. the type of agent, activity and intended use (e.g. number of doses per day), which can be determined by known in the art technologies. It is understood that the effective amount can be the result of empirical and/or individualized (case-by-case) determination on the part of the treating health care professional and/or individual.
- the therapeutic preparations of the invention, the powders, compositions and dosage forms can comprise therapeutically effective amounts of cannabinoid actives in the range of at least about 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-250 mg, and more.
- the therapeutically effective amounts of cannabinoid actives can be in the range of at least about 50-100 mg, 100-150 mg, 150-200 mg, 200-250 mg, 250-300 mg, 300-350 mg, 350-400 mg, 400-450 mg or 450-500 mg.
- treating refers equally to curative therapy and ameliorating therapy.
- the terms encompass any approach for obtaining beneficial or desired therapeutic effects, which may be established clinically by means of physiological, metabolic or biochemical parameters.
- Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization of symptoms, delay or slowing of progression, amelioration or palliation of a condition or a symptom, and remission (whether partial or total).
- the term “palliation” encompasses herein undesirable manifestations of a physiological condition or a symptom which are lessened and/or a progression which is slowed or lengthened, as compared to the same but untreated condition.
- preparations and methods of the invention involve combination therapies, administered simultaneously or in succession with other methods and drugs (also therapeutic agents).
- Therapeutic agents that are relevant can be, although not limited to General Drug Categories, classified by the FDA according to their clinical effects and applicability to common human disorders: analgesics, antacids, antianxiety drugs, antiarrhythmics, antibacterials, antibiotics, antimicotics, anticoagulants and thrombolytics, anticonvulsants, antidepressants, antidiarrheals, antiemetics, antifungals, antihistamines, antihypertensives, anti-inflammatories, antineoplastics, antipsychotics, antipyretics, antivirals, barbiturates, beta-blockers, bronchodilators, cold cures, cholesterol lowering drugs, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, expectorant, hormones, hypoglycemics, immune-suppressive, laxatives, muscle relaxants, sedatives, sex hormones, sleeping drugs, tranquilizer and vitamin supplements, such as omega fatty acids
- an improvement as a result of treatment is identified if there is at least about 5% improvement, or 10% improvement, or at least 25%, or at least 50%, or at least 75%, or at least 100% improvement or more.
- An improvement herein can be interpreted in the sense of individual improvement as well as population improvement.
- the invention provides, inter alia, the following:
- a water-dispersible powder comprising lipophilic nanospheres (submicron nanodroplets) containing a cannabinoid material and further comprising:
- the powder upon dispersion in water the powder produces nanodroplets with a substantially same average size.
- the powder comprises sucrose, trehalose or mannitol and further comprising ammonium glycyrrhizinate and maltodextrin.
- the powder comprises pluronic F-127 or pluronic F68, and further comprising sucrose and maltodextrin.
- the powder comprises sucrose, ammonium glycyrrhizinate, maltodextrin and CMC.
- the cannabinoid material comprises at least one synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- the powder wherein the concentration of a surfactant is in the range of about 3-10% (w/w).
- fraction of lipophilic nanodroplets is in the range of about 10-50% (w/w).
- the powder is in a solidified or compressed solid form.
- the invention further provides a method for producing a water-dispersible powder, the method comprising converting to a powder by lyophilization an emulsion of an oil phase and an aqueous phase; the aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein, the oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- the method comprises:
- the method comprises:
- the nanoemulsion obtained in (iv) and the powder in (v), upon dispersion in water, produce nanospheres (nanodroplets) with a substantially identical average size.
- the step of preparing the initial emulsion in (iii) further comprises high pressure homogenization for at least 1 to 10 runs or more.
- the step of preparing the final emulsion in (iv) involves sonication for at least about 5-60 min.
- the step of preparing the aqueous phase in (i) is carried out at room temperature.
- the oil phase is in the range of about 10-50% (w/w).
- the powder is in a solidified or compressed solid form.
- the homogenized emulsion was sonicated in an ice bath (Ultrasonic cell crusher SKL-750, SYCLON, Probe 1.1 cm diameter as probe no. 10) for 10 min under the conditions of Amplitude: 90%, ON: 2 sec, OFF: 1 sec.
- the resultant powder being a dry fine powder, was stored in closed glass vials.
- the powder was dispersed (0.1-1 wt %) in TDW.
- the samples were vortexed for 1-2 min to obtain a translucent emulsion.
- Droplet size of the O/W nanoemulsion was estimated at Z Average: 160 nm peak 1: 99 nm, 56%; peak 2: 281 nm, 44%, polydispersity index (Pdi): 0.191 (measured by dynamic light scattering (DLS); and after dispersion in water at Z Average: 173 nm peak 1: 94 nm, 43.3%; peak 2: 274 nm, 53.6%; peak 3: 4943 nm, 3.1%, Pdi: 0.227.
- Stability The powder containing 10.5% w/w of olive remained stable after at least 9 weeks of observation.
- compositions of the nanoemulsion and powder are presented in Tables 2 and 3.
- the nanoemulsions were prepared with different surfactant concentrations in the range of 3.15-7.7% w/w in the powder.
- 0.15-0.35 gr pluronic F-127, 1.9-2.1 gr Maltodextrin, 2 gr sucrose, and 14.3 gr TDW were mixed using a magnetic stirrer for 10 min at 35-40° C. until a complete dissolution, all other components, and homogenization and sonication parameters remained the same.
- the effect on the droplet (particle) size is demonstrated in FIG. 2 .
- the nanoemulsions were prepared with 0.25 gr ammonium glycyrrhizinate as surfactant.
- the emulsions were sonicated as in stage IV, Example 1, for the duration of 5 to 60 min, all other components and homogenization parameters remained the same.
- the effect on the droplet (particle) size is demonstrated in FIG. 3 .
- the following formulation was prepared: 0.5 gr Pluronic F127, 4 gr Maltodextrin, 4 gr sucrose, and 28.6 gr TDW were mixed using a magnetic stirrer for 10 min at RT until a complete dissolution.
- 1 gr of the hemp oil was added to the aqueous phase drop ways during homogenization by high shear homogenizer as in stage III, Example 1, this stage was repeated 4 times to obtain a sufficient amount of product for the homogenization step.
- the final emulsion was prepared by HP homogenizer wherein 100 gr of the obtained emulsions were subjected to homogenization for 1 to 6 runs (cycles). The results are demonstrated in FIG. 4 . Droplet size of the O/W nanoemulsion was estimated at the following values:
- a high load formulation (50% hemp oil) was prepared as follows: 2.1 gr ammonium glycyrrhizinate, 13.65 gr Maltodextrin, 14 gr sucrose, and 100.1 gr TDW were mixed as in Example 8. In the next stage, 29.75 gr of hemp oil (50% oil in the powder) was added to the aqueous phase drop ways during homogenization by high shear homogenizer as in Example 8. The final emulsion was prepared by HP homogenizer as in Example 7. Droplet size of the O/W nanoemulsion was estimated at the following values:
- Droplet size after dispersion in water was estimated at Z Average: 181 nm, peak 1: 114 nm, 41%, peak 2: 303 nm, 53%, peak 3: 1763 nm, 6%, Pdi: 0.193.
- CMC Carboxymethyl Cellulose
- the following formulation was prepared: 0.3 gr ammonium glycyrrhizinate, 1.95 gr Maltodextrin, 2 gr sucrose, 0.085 gr CMC, (Sigma, ultra-low viscosity, 36038-4, cas: 9004-32-4), and 14.3 gr TDW were mixed for 10 min at RT until a complete dissolution and acquisition of an aqueous solution.
- 4.165 gr of hemp oil was added to the aqueous phase, homogenized drop ways during homogenization by high shear homogenizer as in Example 1 for the duration of 10 min, followed by sonication as in Example 7.
- Droplets size of the O/W nanoemulsion was estimated at Z Average: 145.7 nm peak 1: 30 nm, 4%; peak 2: 100 nm, 49%; peak 3: 307 nm, 47%, Pdi: 0.161; and after dispersion in water at Z Average: 190 nm, peak 1: 180 nm, 94%, peak 2: 963 nm, 3%, peak 3: 5151 nm, 3%, Pdi: 0.322.
- Example 7 The presently described tablets were prepared from the powder obtained in Example 7 using a tablets compresser (PIKE Technologies, CrushIR TM, under 9-9.5 tons), certain illustrations thereof are provided in FIG. 6 .
- PIKE Technologies, CrushIR TM PIKE Technologies, CrushIR TM, under 9-9.5 tons
- Each 300 mg or 650 mg tablet contained the hemp oil powder formulation of the invention (HOP), and additional functional agents from state of the art in respective concentrations.
- HOP hemp oil powder formulation of the invention
- One optional application of such tables is for sublingual administration.
- Certain examples of the produced tablets are given below:
- the tablets were subjected to DLS measurements in order to evaluate droplets size, which revealed that for all types of tables the droplets size were still in the nanometric range, e.g., 250-290 nm.
- Disintegration profiles of the tablets were further studied comparing HOP table No. 8 (see Example 11) and Centrum Junior sublingual tablet. Both types of tablets, each 300 mg, were immersed in TDW 37° C. under vigorous shaking (see FIG. 7 ). Tablets were removed from water every 2 min, excess liquid was absorbed into paper, and tablets were weighed.
- the disintegration profile (tablet weight vs. dissolution time) of the HOP tablet was essentially similar to the Centrum tablets (see FIG. 8 ).
- three different redispersed emulsions were prepared as follows: 15 mg of cannabis oil powder, (contains 30% oil in powder), were dispersed, by a 20 second of vortex, in 3 ml of aqueous medium to obtain emulsion concentration of 0.5% w/w of the powder in the water.
- the pH of the first aqueous medium was 1.2, mimicking stomach conditions.
- the pH of the second aqueous medium, distilled water, was 5.5 and the pH of the third aqueous medium was 6.8, mimicking intestines conditions.
- one droplet of the dispersed emulsion was mixed with 2 ml of the certain aqueous medium and the sample was measured by DLS zetasizer equipment at TO and after 24 h. Each sample was prepared in duplicate and measured in 3 cycles for each sample.
- Formulation comprising Cannabis oil, 19% oil in powder.
- the final powder contains 8 mg THC/gr and 2 mg CBD/gr.
- the following exemplary formulation was prepared: 1.44 gr Pluronic F127, 8.5 gr Maltodextrin, 9.6 gr sucrose, one stevia tablet, weigh 82 mg which contains 12 mg of stevia dissolved in 2 gr of worm water and 67 gr TDW were mixed using a magnetic stirrer for 10 min at RT until a complete dissolution.
- 4.56 gr of the cannabis oil were added to the aqueous phase drop ways during homogenization by high shear homogenizer as in stage III, Example 1.
- the final emulsion was prepared by HP homogenizer as in Example 7 but with microfluidizer, M110P technology, equipment. Droplet size of the O/W nanoemulsion was estimated at the following values:
- the lyophilization step was as in stage V, Example 1. Droplet size after dispersion in water was estimated at Z Average: 224 nm peak 1: 233 nm, 100%, Pdi: 0.194.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses particular water-dispersible solid formulation of a cannabinoid or a cannabis extract, wherein they are present in the form of a nanoemulsion, and upon dispersion in water said formulation produces nanoparticles (droplets of a submicron size) with an average size of up to about 500 nm. The present disclosure further relates to methods of making thereof, as well as therapeutic applications in humans for treating disorders and broader application for a range of medical conditions.
Description
- This application is a continuation of and claims the benefit of U.S. application Ser. No. 16/958,341 filed Jun. 26, 2020, pending (now allowed), which is a National Phase Entry of PCT International Application No. PCT/IL2019/050268 which was filed on Mar. 11, 2019, which claims priority to Israel patent application 261132, filed Aug. 13, 2018, all of which are hereby incorporated by reference in their entireties.
- The invention generally relates to formulations of cannabinoids, more specifically formulations as water-dispersible powders containing nanodroplets of a cannabinoid material, methods of producing thereof, as well as dosage forms and uses thereof for clinical purposes.
- Medicinal value of cannabis is well documented. Cannabinoids, the active ingredients of cannabis, are produced in significantly higher amounts in resin-producing inflorescences of female cannabis plants. Various types of cannabis such as C. Sativa, C. Indica, C. Ruderalis may produce more than 100 different types of cannabinoids in various concentrations and proportions. The two main cannabinoids, the tetrahydrocannabinol (THC) and cannabidiol (CBD), have been related to a number of biologically important activities in humans, and mammals in general.
- The mammalian endocannabinoid system is a signal transduction system acting predominantly in the brain, and also in peripheral tissues. Several cannabinoid receptors have been identified so far, the most prominent are
CB types 1 and 2 (CB1 and CB2). The endocannabinoid system has been implicated in maintenance of the normal mammalian homeostasis, including systems of movement control, pain, appetite, memory, immunity and inflammation, and others. This explains the high therapeutic potential of cannabis-based medicines, and exogenous cannabinoids, and their broad clinical applications. - Beneficial effects of cannabis have been revealed in a number of clinical conditions such as pain (pain in cancer, fibromyalgia related and neuropathic pain), inflammatory diseases (e.g. inflammatory bowel diseases, Crohn's disease, ulcerative colitis), posttraumatic stress disorder (PTSD), loss of appetite/anorexia, sleep disorders, multiple sclerosis (MS), epilepsy, autism, schizophrenia, and other disorders. In terms of broader biological effects, analgesic, antiemetic, antioxidative, neuroprotective and anti-inflammatory effects are only a few among various activities attributed to the two most studied cannabinoids THC and CBD.
- Currently, medical cannabis is administered primarily through smoking or consumed orally in the form of oil, cookies, chocolates, etc. The majority of these products are not standardized with respect to cannabinoid compositions and doses.
- A number of oral formulations of cannabinoids and cannabis-derived medicines are commercially available today by prescription for specific clinical indications. Marinol capsules containing dronabinol, a synthetic Δ9-THC isoform, in sesame oil, have been approved in a number of countries as an antiemetic for cancer patients under chemotherapy and patients with AIDS. Cesamet capsules with nabilone, a synthetic THC analog, have been approved as a Marinol substitute. More recent formulations Namisol tablets with pure THC and Arvisol tablets with pure CBD approved for Alzheimer's disease and chronic neural pain, and Sativex (nabiximols), an oral spray containing THC and CBD, for multiple sclerosis.
- One general problem with pharmaceutical formulations of cannabinoids ensues from their highly lipophilic nature. Most of the existing cannabinoid- and cannabis-based formulations use relatively high concentrations of oil to achieve therapeutically effective concentrations of actives. Other major disadvantages, related to the afore-mentioned, is revealed in their poor bioavailability and high patient variability, as well as relatively short product life due to formulation instability.
- Therefore, there is a clear incentive for the development of new and more progressive formulations of cannabinoids and cannabis-based preparations employing new technologies, such as nanoemulsions, microcapsules and other formulations.
-
- [1] WO 2013/172999
- [2] WO 2013/108254
- [3] WO 2015/171445
- [4] WO 2016/147186
- [5] WO 2016/135621
- [6] WO 2017/180954
- [7] US2016/0058866
- [8] “Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms”, Edited by Vikas Anand Saharan, published by Bentham Science,
Chapter 2, pages 19-40, 11/05/2017 - [9] “Lyophilization of Cationic Lipid—protamine—DNA (LPD) Complexes”, Bei Li et al, Journal of pharmaceutical science, Vol 89:3, 355-364 (2000).
- The present invention provides solid formulations of cannabinoids or cannabis-based extracts in a form of readily water-dispersible fine powders or tablets containing oil droplets of predetermined sizes. One of the distinctive features of formulations of the invention is in their ability to recover, upon contact with water or a water-based environment, the same oil droplets, in substantially the same size. Specifically, the inventors have developed a solid-based delivery system derivable from an initial fine-tuned nanoemulsion that is tailored to contain lipophilic nanodroplets of a desired size. The conversion of the nanoemulsion to the solid-based delivery system, i.e., powder, maintains the integrity, content and size of the nanodroplets. Their integrity, content and size are further maintained when the solid-based delivery system is re-dispersed in water or when it comes into contact therewith.
- This delivery system is not only unique, but even more so surprising as reconstitution of solid nanoemulsions typically results in a distortion of their form and size, usually in favor of larger spheres. Further studying the effect of various components and proportions thereof on the nanodroplets size, present in the initial nanoemulsion and the nanodroplets resulting from dispersing the powder in water, the inventors have found that this feature is highly exclusive and characteristic of a selection of compositions. In an oil model, the inventors demonstrated that in order to retain this feature the formulations should comprise at least one cryoprotectant such as sucrose, trehalose, or mannitol, at least one surfactant as ammonium glycyrrhizinate, pluronic F-127, F68, and optionally at least one carbohydrate such as maltodextrin and carboxymethyl cellulose (CMC). Certain combinations of these components and their ensuing effects on particle size are presently illustrated.
- The inventors also demonstrated that particle size can be further modulated or controlled by selecting material combinations or by certain steps in the method of production of formulations of the invention, such that the size of the nanodroplets may be pre-tailored to be within 50 and 900 nm. This may be achieved, for example, by employing steps of lyophilization, homogenization and/or sonication to achieve the powder forms.
- Further, the presently described solid formulations may be loaded with an large amounts of the lipophilic/oil fraction; amounts that under some embodiments can be as high as 75% of the powder form or up to as much as 50% of the powder form (w/w). This feature is particularly important in view of the highly lipophilic nature of cannabinoids, their poor water-solubility and lability to thermal and photolytic degradation and oxidation, all making the design of cannabinoid formulations particularly challenging.
- Liquid pharmaceutical formulations of cannabinoids are not always achievable. Despite the expected advantages (e.g., easy to swallow, uniform delivery and rapid onset), such formulations usually require relatively large volumes of solvents. With solid formulations, meant to overcome this disadvantage, dissolution of cannabinoids imposes a critical problem. Thus, the feature of high loading with respect to the lipophilic/oil fraction containing the cannabinoids, this without alcohols or other water-miscible solvents, or without any solubilizing agents, makes the cannabinoid formulations of the invention especially advantageous in terms delivery of therapeutically effectives doses of actives.
- Still on this feature, the capability to modify or control loading of the oil fraction would be one way to control doses of actives in a formulation of a certain type, being it a cannabinoid-based (e.g., THC and/or CBD) or a cannabis-based formulation. Specifically for cannabis-based formulations, this provides a standardized pharmaceutical raw material with known concentrations of cannabis (unlike when dealing with inflorescences). In other words, the invention provides a solid homogeneous formulation of highly hydrophobic actives, in an administrable form, with relatively high load of actives, while being exempt from co-solvents such as alcohols. The formulations of the invention while being solid and compact are at the same time easily dispersible in water, with the actives retaining their properties in the oil phase, providing increased stability.
- According to additional experiments, formulations of the invention remained stable for a period of 12 months or more. In this connection, it should be noted that the powder formulations of the invention can be further solidified or compressed into a solid form, such as a tablet and films, without affecting their stability and functionality.
- The present invention further provides a method for producing such powder formulations. The methods of the invention have been presently exemplified using hemp oil and cannabis oils. Methods of the invention can be adapted to include one or more specific cannabinoids, synthetic or isolated from natural sources, and also complete or fractionated extracts of cannabis plants, in various proportions and combinations.
- Another important objective of formulations of the invention is to maximize the potential of an increased bioavailability, especially for oral dosage forms. Achieving an effective oral delivery is essential for any successful therapeutic strategy, in terms of maximizing therapeutic effects, achieving stable and predictable drug plasma levels and pharmaco-dynamic effects, and as a consequence, increased patient compliance. Cannabinoids, however, have been proven particularly difficult to deal with due to their limited solubility in plasma and consequently limited bioavailability, and significant first pass effect. Thus there is still an unmet need for effective oral cannabinoid- and cannabis-based formulations, particularly in powder oral forms. The cannabinoid formulations of the invention due to their particular physical properties, being lipo-nanospheres of a particular particle (droplets) size, have a potential to overcome these limitations, in terms of increased dissolution or dispersion of actives, increased bioavailability and protection of actives from P-gp metabolism.
- It is therefore yet another advantageous feature of formulations of the invention that they can be easily adapted to oral dosage forms such as tablets and sublingual tablets or capsules with various controlled doses of actives, i.e., cannabinoids or cannabis extracts. Such preparations can comprise additional therapeutic agents tailored for specific therapeutic indications which could benefit from cannabinoids and cannabis-based medicines. They can further comprise minerals, antioxidants, nutrients and vitamins in forms consumed directly with food.
- The powder formulations can be further adapted for other administration methods, such as inhalation methods and devices, by using suitable pharmaceutical excipients. For example, in reconstituted forms the formulations of the invention can be further adapted as creams and aqueous dispersions for topical and transdermal administrations or generally as depositories.
- Ultimately, the presently described formulations and dosage forms can be further improved by the addition of permeation enhancers to increase bioavailability, and controlled release agents in the form of a matrix or a coating using know in the art methods.
- The following figures illustrate certain advantageous features of the invention. It is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the embodiment of the invention.
-
FIG. 1A-B shows Cryo TEM analysis of the formulation of the invention for (FIG. 1A ) the nanoemulsion (10% in water) with droplet size in the range of 80-120 nm; and (FIG. 1B ) the dispersed powder (1% in water) with droplet size in the range of 70-130 nm (see Example 1). -
FIG. 2 shows the effect of surfactant concentration (between 3.2-7.7% w/w) on droplet size of a formulation of the invention (in the range of 251-450 nm) (see Example 5). -
FIG. 3 shows the effect of sonication time (between 5 to 60 min) on the droplet size of the formulation (in the range of 60-220 nm) (see Example 6). -
FIG. 4 shows the effect of high pressure homogenization (between 1-6 runs) on droplet size of the formulation (in the range of 167-198 nm) (see Example 7). -
FIG. 5 shows the effect of hemp oil concentration (between 19-50% w/w) on droplets size of the nanoemulsion (dashed) and dispersed powder (solid) with droplets in the range of 130-190 nm (see Example 8). -
FIG. 6 shows 300 mg and 650 mg tablets containing hemp oil powder (HOP) and additives (magnesium stearate (MS), Glycine (G), PVP (40,000)):Tablets 1=HOP 650 mg; 2=HOP+MS; 3=HOP+G; 4=HOP+PVP; S=HOP+MS+G; 6=HOP+G+PVP; 7=HOP+PVP+MS; 8=HOP+MS+G+PVP (see Example 11). -
FIG. 7 shows experiments mimicking sublingual dissolution of the HOP and Centrum tablets (see Example 12) -
FIG. 8 shows tablet weight vs. disintegration time comparing the HOP (grey squares) and Centrum pill (black dots) tablets. - By describing specific embodiments of the invention it is not meant that this invention is limited to particular methods, and experimental conditions described, as such methods and conditions may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
- Thus, the invention first provides a water-dispersible powder comprising lipophilic nanospheres (or nanodroplets or lipo-nanospheres) having an averaged size between 50 and 900 nm, the nanospheres having an adsorbed layer of at least one solid surfactant and containing a cannabinoid material, wherein the at least one solid surfactant is selected from ammonium glycyrrhizinate, pluronic F-127 and pluronic F68; the powder further comprising at least one solid cryoprotectant selected from sucrose, trehalose and mannitol, and optionally at least one solid carbohydrate selected from maltodextrin and carboxymethyl cellulose (CMC); wherein the nanospheres structure and size is substantially maintained upon dissolution in a water containing environment.
- As known in the art pluronic F-127 and pluronic F-68 are BASF ethylene oxide/propylene oxide block copolymers of known structures and molecular weights.
- The powder of the invention is a solid form comprising a plurality of material nanospheres, each having a shell of at least one surfactant and containing the cannabinoid material. The expression “lipophilic nanospheres . . . having an adsorbed layer of at least one solid surfactant and containing a cannabinoid material” refers to the fact that these nanospheres, used interchangeably with nanodroplets or lipo-nanospheres, are material entities that are spherical or substantially spherical in shape, contain a cannabinoid material and surface-adsorbed by a film of the at least one surfactant. The nanospheres may have an adsorbed layer consisting of the at least one surfactant or have an adsorbed layer that comprises at least one surfactant as well as an amount of the other material components present in the powder.
- The powder of the invention is derivable from a nanoemulsion that comprises a plurality of oil nanodroplets comprised of the cannabinoid material. In the nanoemulsion, the nanodroplets are of a size between 50 and 900 nm that is conserved in the solid powder. In fact, when the nanoemulsion is converted to a solid formulation, i.e., to the powder, the integrity, content and size of the nanodroplets is maintained.
- The nanodroplets integrity, content and size are further conserved when the solid-based delivery system is re-dispersed in water or when it comes into contact therewith. The nanodroplets integrity, content and size are unaffected by acidic conditions and therefore powders of the invention may be delivered in vivo, ensuring safe and effective delivery of the nanodroplets cargo at pH values between 1 and 7.
- Thus, for a variety of applications, e.g., medicinal applications and non-medicinal applications, powders with pre-tailored populations of oil droplets(nanospheres) of narrow size distributions may be prepared, to meet the target uses.
- Powders with nanospheres having an averaged diameter as low as 50-100 nm as well as nanospheres having a submicron diameter, e.g., as high as 750-900 nm, are preparable by methods of the invention. Thus, the powders of the invention, as defined, may comprise nanospheres of a size between 50 and 900 nm, or between 50 and 100 nm, or between 50 and 150 nm, or between 50 and 200 nm, or between 50 and 250 nm, or between 50 and 300 nm, or between 50 and 350 nm, or between 50 and 400 nm, or between 50 and 450 nm, or between 50 and 500 nm, or between 50 and 550 nm, or between 50 and 600 nm, or between 50 and 650 nm, or between 50 and 700 nm, or between 50 and 750 nm, or between 50 and 800 nm, or between 50 and 850 nm, or between 100 and 150 nm, or between 100 and 200 nm, or between 100 and 250 nm, or between 100 and 300 nm, or between 100 and 350 nm, or between 100 and 400 nm, or between 100 and 500 nm, or between 100 and 550 nm, or between 100 and 600 nm, or between 100 and 650 nm, or between 100 and 700 nm, or between 100 and 750 nm, or between 100 and 800 nm, or between 100 and 850 nm, or between 150 and 900 nm, or between 150 and 800 nm, or between 150 and 700 nm, or between 150 and 600 nm, or between 150 and 500 nm, or between 150 and 400 nm, or between 150 and 300 nm, or between 150 and 200 nm, or between 200 and 900 nm, or between 200 and 800 nm, or between 200 and 700 nm, or between 200 and 600 nm, or between 200 and 500 nm, or between 200 and 400 nm, or between 200 and 300 nm, or between 250 and 900 nm, or between 250 and 800 nm, or between 250 and 700 nm, or between 250 and 600 nm, or between 250 and 500 nm, or between 250 and 400 nm.
- In some embodiments, the nanospheres have an averaged diameter of between 200 and 400 nm, or between 250 and 400 nm, or between 250 and 350 nm, or between 200 and 500 nm, or between 250 and 500 nm.
- In some embodiments, the nanospheres have an averaged diameter of between 100 and 400 nm, or between 150 and 400 nm, or between 150 and 350 nm, or between 100 and 500 nm, or between 150 and 500 nm.
- In some embodiments, the nanospheres have an averaged diameter of between 200 and 250 nm, or between 250 and 300 nm, or between 300 and 350 nm, or between 350 and 400 nm, or between 400 and 450 nm or between 450 and 500 nm.
- In some embodiments, the nanospheres have an averaged diameter of between 200 and 210 nm, or between 210 and 220 nm, or between 220 and 230 nm, or between 230 and 240 nm, or between 240 and 250 nm, or between 250 and 260 nm, or between 260 and 270 nm, or between 270 and 280 nm, or between 280 and 290 nm, or between 290 and 300 nm.
- In some embodiments, the nanospheres have an averaged diameter of between 210 and 310 nm, or between 220 and 320 nm, or between 230 and 330 nm, or between 240 and 340 nm, or between 250 and 350 nm, or between 260 and 360 nm, or between 270 and 370 nm, or between 280 and 380 nm, or between 290 and 390 nm, or between 300 and 400 nm.
- In some embodiments, the powder of the invention, upon dispersion in water, produces nanodroplets (spheres in the submicron scale) with an average size of between 50 and 900 nm, being an averaged size that is substantially identical. However, an increase or decrease in the size of the nanodroplets may be achieved upon dispersion. For example, a difference between the nanodroplets in the initial emulsion and the those in the dispersed medium may be tailored to about ±20-30 nm for emulsions with 10% dispersed fraction of the oil droplets and no higher than ±100 nm for emulsions with 30% dispersed fractions. The exact range can vary as indicated above, e.g., between 50-100 nm, 100-200 nm, 200-300 nm, 300-400 nm, 400-500 nm, and in certain embodiments more than 500 nm. The exact droplets size and size distribution can be controlled by changing the composition of the emulsion or features of the emulsion, such as phase fraction and surfactant concentrations and by changing the preparation parameters such as pressure and number of cycles in case high pressure homogenizer is used for preparing the emulsions.
- Thus, the expression “nanospheres with a substantially same average size” supports the fact that the nanospheres present in the powder conserve their size upon reconstitution of the powder in water or a water containing environment. The size is said to be “substantially the same”, namely the average size is identical to that in the powder or is within ±10% of the original size.
- In some embodiments, the powder of the invention comprises sucrose, trehalose or mannitol, a cannabinoid material and further ammonium glycyrrhizinate and maltodextrin.
- In some embodiments, the powder comprises pluronic F-127 or pluronic F68, a cannabinoid material and further sucrose and maltodextrin.
- In some embodiments, the powder comprises sucrose, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises ammonium glycyrrhizinate, Maltodextrin, sucrose and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, ammonium glycyrrhizinate, maltodextrin and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, ammonium glycyrrhizinate, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, ammonium glycyrrhizinate, maltodextrin and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, pluronic F-127, maltodextrin and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, pluronic F-127, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, pluronic F-127, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, pluronic F-127, maltodextrin and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, pluronic F-68, maltodextrin and a cannabinoid material.
- In some embodiments, the powder comprises mannitol, pluronic F-68, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, pluronic F-68, maltodextrin, CMC and a cannabinoid material.
- In some embodiments, the powder comprises trehalose, pluronic F-68, maltodextrin and a cannabinoid material.
- The at least one surfactant may be comprised in the powder in an amount ranging between about 1 and 10% (w/w), more specifically as high as 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% (w/w) surfactant.
- In some embodiments, the amount of the surfactant may be less than 1% or more than 10%.
- The amount of the at least one carbohydrate in the powder may be between 20 and 40% (w/w).
- The amount of CMC, where used, may be about between 0.1 and 3% (w/w). In some embodiments, the mount of CMC is about 1%.
- In some embodiments, powders of the invention comprise an amount of the cannabinoid material in the range of about 10-50% (w/w), more specifically in the range of 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50% (w/w), or more.
- The cannabinoid material may be a synthetic or natural cannabinoid(s), a cannabis extract(s) or a fraction thereof. In the broadest sense, this term denotes the entire class of chemical compounds, cannabinoid/cannabinoid agonists/cannabinoid-related compounds, acting with various affinities on the endogenous cannabinoid receptors (CB1 and CB2). This group of ligands include the endocannabinoids (produced naturally by humans and animals), phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially).
- Anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (such as Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, spasticity, autism, tuberculosis, inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, irritable bowel syndrome, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, fibromyalgia, graft versus host disease, constitute only a partial list of clinical conditions that are treatable by cannabinoid/cannabinoid agonists/cannabinoid-related compounds.
- The term “cannabinoid material” further refers to the classical cannabinoids originating from or mimicking the natural cannabinoids in a cannabis plant. The main classes of the classical cannabinoids are shown in Table 1 below.
- In some embodiments, the powders of the invention comprise nanospheres with one or more cannabinoids belonging to one or more of the above classes.
- In other embodiments, the powders of the invention comprise nanospheres with extract cannabis oils. Extract cannabis oils can be full extracts (FECO), one example of those is Rick Simpson Oil (RSO), or extracts enriched in specific cannabinoids (THC or CBD). Such extract oils can be obtained from C. Sativa, C. Indica, C. Ruderalis strains, more potent preparations are obtained from female flowers.
- It is yet another aspect of the invention to provide a method for producing a water-dispersible powder of the invention, the method comprising converting a nanoemulsion comprising at least one cannabinoid material to powder by a water-removal step, as disclosed herein, e.g., lyophilization, oven drying and spray-drying.
- In some embodiments, the nanoemulsion comprising the at least one cannabinoid material comprises (a) an aqueous formulation comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein; and (b) an oil comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- In some embodiments, the method comprises:
-
- (i) preparing or obtaining a nanoemulsion comprising (a) an aqueous formulation comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein; and (b) an oil (e.g., an oil formulation) comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof; and
- (ii) converting the nanoemulsion to a powder through removal of water, e.g., by lyophilization, oven drying or spray-drying.
- In some embodiments, the method comprises preparing an aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined above.
- In some embodiments, the method comprises preparing an oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- In some embodiments, the method comprises:
-
- (i) preparing an aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined above
- (ii) preparing an oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof,
- (iii) preparing an emulsion by mixing (e.g., by a homogenizer) the oil phase and the aqueous phase,
- (iv) optionally sonicating/homogenizing the emulsion by e.g., a high pressure homogenizer and
- (v) converting the nanoemulsion to a powder, e.g., by lyophilization.
- One of the important attributes of the method is that the nanoemulsion obtained, the powder formed, and the emulsion obtained upon dispersion of the powder in water produces nanospheres (nanodroplets) of substantially the same size, being a submicron size, and an average size as recited above.
- In certain embodiments, the step of preparing the emulsion comprises high pressure homogenization of both phases for at least 1 to 10 runs, more specifically for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 runs or more.
- In other embodiments, the step of preparing the emulsion can involve sonication for at least about 5-60 min, more specifically for at least about 5-10 min, 10-20 min, 20-30 min, 30-40 min, 40-50 min, 50-60 min or more.
- In still other embodiments, the step of preparing the aqueous phase is carried out at room temperature.
- It is another aspect of the invention to provide water-dispersible powders produced by a method of the invention, powders with the same physical and chemical properties in terms of particle size, type of constituents, actives and loading of actives as described above.
- It should be noted that in certain embodiments the powders of the invention can be further solidified or compressed into solid forms. The solid forms can be tablets, capsules or films, as presently exemplified.
- As powders of the invention retain their physical and chemical properties at room temperature for a period of at least 12 months or more, i.e., the powders of the invention remain stable for at least about 6 months, 9 months, 12 months or more at room temperature, they are easily convertible into pharmaceutical preparations of a variety of forms, suitable for a variety of administration modes and for use in a variety of medicinal applications.
- It is thus another aspect of the invention to provide a pharmaceutical composition comprising water-dispersible powders, as above.
- The compositions may be solid compositions or may be reconstituted compositions, in which case—in addition to the water-dispersible powders may further comprise a pharmaceutically acceptable buffer or liquid carrier.
- In numerous embodiments, the pharmaceutical compositions of the invention comprise powders with synthetic or natural cannabinoids, cannabinoid combinations, cannabis extracts or fractions thereof.
- In some embodiments, the composition of the invention comprise a synthetic or a natural cannabinoid which is one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CB G), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), and a derivative, a precursor or an acid-form of any of the aforementioned.
- All types of cannabinoids (those listed in Table 1 and others known as cannabinoids) are derived from cannabigerol-type compounds and differ mainly in the way this precursor is cyclized. The classical cannabinoids are derived from their respective 2-carboxylic acids (2-COOH, also denoted with —A) by decarboxylation (catalyzed by heat, light, or alkaline conditions). Of particular relevance to the invention are tetrahydrocannabinol and cannabidiol acid precursors, THC-A and CBD-A.
- As has been mentioned, in numerous embodiments, the composition of the invention can comprise a full or partial extract in the form of a cannabis oil obtained from C. Sativa, C. Indica, C. Ruderalis strains, flowers and other parts.
- Oil extracts can be made using linseed oil, hemp oil, sesame oil, olive oil (the most common example), castor oil, chia seed oil, cotton oil, corn oil, coconut oil, sunflower oil, soybean oil, canola oil, etc. The linseed, castor and sesame oils are particularly advantageous as they contain alpha-linolenic acid, an essential nutrient.
- Another advantage of cannabis-based compositions is in their added content of terpenes, sesquiterpenes, carotenes, flavonoids, being present in various combinations and proportions, and which contribute to absorption, activity and further to flavor-, odor-, and color-imparting properties, in the sense of being more user-friendly.
- In numerous embodiments, compositions of the invention can comprise additional therapeutic agents. This feature is explained in detail below. In general terms, in view of the exceptionally board clinical applicability of cannabinoids and cannabis-based medicines there are a large number of applicable agents, e.g., antibiotic, anti-epileptic, anti-spastic, anti-inflammatory, analgesic and antipsychotic and others.
- In numerous embodiments, compositions of the invention can further comprise antioxidants, minerals, nutrients, vitamins or combinations thereof, which can be consumed together with food or as food supplements. In this respect, compositions of the invention are particularly advantageous as many vitamins, such as vitamin E, have the same problems of solubility and bioavailability as the cannabinoids.
- In terms of actives, compositions of the invention comprise up to about 75%, 60%, or 50% (w/w) actives, more specifically up to 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% (w/w) actives, and in certain embodiments even more. In this context, the term “active” refers to a cannabis oil or an oil form of the cannabinoid material.
- In other numerous embodiments, compositions of the invention can further comprise antioxidants, absorption enhancers, color- and flavor-imparting agents, preservatives, stabilizers, salts, in various combinations. Various sweeteners, taste modifiers, antioxidants, preservatives which are well known in the art include taste modifiers such as artificial sweeteners, flavorings as strawberry and peppermint oil, for example, plant sweeteners, sugars, honey, Stevia, steviol, glycosides, citrate, acids, menthol, anise, eucalyptus oil, fennel, natural antimicrobial substances and natural antioxidant (e.g. extracts of murta, oregano, rosemary, borage), antioxidants such as vitamins E (tocopherol) and C and their derivatives, butylated hydroxyanisole (BHA), butylated hydroxytolune (BHT) recognized as GRAS, and sulfides; any sweetener allowed for oral administration such as sugar, glucose, sucralose, glycine, cyclamate, sucrose, saccharin, fructose, maltose, stevia extract, sodium saccharine; salts such as NaCl, NaHCO3, Na2CO3, citrate, and others.
- Other additives can be used, such as various solidifiers and viscosity modifiers, in various doses such as stearic acid, ascorbyle palmitate, palmitic acid, or hexadecanoic acid, polymers, magnesium stearate, cetyl alcohol, cetostearyl alcohols, stearyl alcohol; and specific viscosity enhancers such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), sodium alginate, PG alginate, polyacrylic acids such as Carbopol, mucoadhesive polymers, Carbophils, celluloses, cellulose-ethers such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hyaluronic acid (HA), alginic acid, xanthan gum, pectins, carrageenan.
- In certain embodiments the compositions of the invention can further comprise a controlled release agent. This feature is explained in detail further below, in the context of oral dosage forms. In general terms, this feature here encompasses controlled and modifying release agents provided in the form of matrix and/or coating.
- It should be noted that compositions of the invention are adaptable for any type of administration, as known in the medicinal or veterinary sciences. Powders as well as reconstituted formulations may be configured or engineered or adapted or selected or used for topical administration, enteral administration (e.g., including all systemic administration routes involving administration via the gastrointestinal tract), or parenteral administration (e.g., including all systemic administration routes, not involving administration via the gastrointestinal tract). Non-limiting administration routes effective for administration or powders or reconstituted formulations of the invention include oral, sublingual, mucosal, aerosol, inhalation, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal and vaginal administrations.
- As has been mentioned, it is another aspect of the invention to provide dosage forms for oral or sublingual administrations comprising the previously described compositions and powders.
- The oral dosage forms of the invention can be generally characterized as comprising at least one synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- In numerous embodiments, the oral dosage forms of the invention can comprise at least one synthetic or natural cannabinoid which is THC, CBD, CBN, CBG, CBC, CBL, CBV, THCV, CBDV, CBCV, CBGV, CBGM, as a derivative, a precursor or an acid-form.
- In yet other embodiments, oral dosage forms of the invention can comprise a cannabis extract or a fraction obtained from a strain C. Sativa, C. Indica, C. Ruderalis or a combination thereof.
- As noted above, the oral dosage forms of the invention can further comprise additional therapeutic agents, minerals, nutrients, vitamins in various concentrations and combinations.
- Of particular interest are oral dosage forms with a controlled release property. The term “controlled release” refers to a property or a modification enabling to achieve time dependent release, sustained release, prolonged release and also pulse release, i.e., delayed release of the drug. The term further relates to gastro-resistance, i.e., a property or a modification enabling to achieve pH-controlled drug release, gastrointestinal targeting, colon delivery, protection of acid-sensitive actives, protection of gastric mucosa from aggressive actives. In this sense, gastro-resistance is also targeted drug release. Gastro-resistant coatings and modifications are also known to improve storage stability.
- Improved gastro-resistance and/or controlled release can be achieved by modification of and/or coating using various pharmacological technologies, such as use of poly(meth)acrylates or layering. A well know example of poly(meth)acrylate coating which has been widely used in the pharmacological industry to achieve targeted and controlled drug release is EUDRAGIT®. Another important feature of poly(meth)acrylate coating is protection from external influences (moisture) or taste/odor masking to increase patient compliance.
- Certain solid oils can be added to facilitate controlled release, such as mono-, di- and triglyceride oils, in general, and trilaurin, tricaprin, tripalmitin, trimyristin, glyceryl, hydrogenated palm oil distearate, hydrogenated castor oil, hydrogenated vegetable oil, in particular.
- In certain embodiments oral dosage forms of the invention can comprise matrix modifying/controlled release materials, which include, although not limited to, glycerides, waxes, fatty acids, methyl acrylate, methylmethacrylate, ethyl cellulose, poly(vinyl alcohol) (PVA), poly(vinyl pyrrolidone) (PVP), starch, polysaccharides, and others.
- In other embodiments, oral dosage forms of the invention can be coated with hydroxypropyl methylcellulose, poly(meth)acrylates, methyl acrylate-methacrylic acid copolymers, cellulose acetate, polyvinyl acetate phthalate, and other types of coatings.
- In numerous embodiments, the oral dosage forms of the invention can be provided in the form of a tablet or a capsule, both being the most popular and convenient methods of oral drug delivery.
- With respect to capsules, optionally a capsule can be coated with a gastro-resistant coating using GRAS-based materials.
- In further embodiments these dosage forms can use a secondary package, such as a blister (PVC/PVDC—Alufoil), a bottle, an aluminum pouch, others.
- It should be appreciated that one of the particular features of the presently described dosage forms is their stability at room temperature.
- In yet another aspect, the above described powders, composition and dosage form of the invention can be applied for the treatment and alleviation of a number of disease and medical conditions, specifically those wherein beneficial effects of cannabinoids or cannabis-based medicines have been previously demonstrated. In other words, the invention provides a range of therapeutic methods for treating diseases or medical conditions related to beneficial effects of cannabinoids or cannabis, by application of presently described powders, pharmaceutical compositions or dosage forms.
- As has been noted, the therapeutic methods of the invention can be applied to a wide range of human conditions, including inflammatory, neurological, psychiatric disorders, malignancies and further immune, metabolic disorders, nutritional deficiencies, infectious diseases, and types of gastrointestinal disorders, cardiovascular disorders, and various types of pain, including chronic and neuropathic pain.
- Considering the present level of knowledge regarding clinical applications of cannabinoids in young and elderly patients, it is projected that the presently described preparations and methods can be applied to, although not limited to depression, sleeping disorders, eating disorders, cancer, multiple sclerosis, graft versus host disease (GVHD), Parkinson's, epilepsy, autism, tuberculosis, ulcerative colitis, morbus Crohn, inflammatory bowel disorder (IBD), irritable bowel syndrome (IBS), appetite stimulant, appetite depressant, obesity, nausea, neuropathic pain, anxiety, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), gastrointestinal disorders, hypertension, incontinence, pruritus, arthritis, arthrosis, rheumatic inflammation, insomnia, mycosis, local and/or chronic pain, inflammation, attention deficit and hyperactivity disorder (ADDH), vomiting, atopic dermatitis, fibromyalgia, AIDS, mood disorders, erectile dysfunction, premature ejaculation, nutritional deficiency.
- It should be appreciated that the presently described preparations and methods are applicable to subjects that are infants, adolescents or adults.
- It should also be noted that powders, compositions and dosage forms of the invention are applied in therapeutically effects amounts. In general terms, a “therapeutically effective amount” (also a pharmacologically or a pharmaceutically or a physiologically effective amount) denotes an amount of the cannabinoid material needed to achieve the anticipated or desired physiological response. The precise amount is dependent on numerous factors, e.g. the type of agent, activity and intended use (e.g. number of doses per day), which can be determined by known in the art technologies. It is understood that the effective amount can be the result of empirical and/or individualized (case-by-case) determination on the part of the treating health care professional and/or individual.
- In numerous embodiments, the therapeutic preparations of the invention, the powders, compositions and dosage forms, can comprise therapeutically effective amounts of cannabinoid actives in the range of at least about 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-250 mg, and more.
- In further embodiments, the therapeutically effective amounts of cannabinoid actives can be in the range of at least about 50-100 mg, 100-150 mg, 150-200 mg, 200-250 mg, 250-300 mg, 300-350 mg, 350-400 mg, 400-450 mg or 450-500 mg.
- Larger therapeutic doses can involve multiple daily administrations.
- The terms “treating”, “treatment” or “therapy” or any lingual variation thereof, refer equally to curative therapy and ameliorating therapy. The terms encompass any approach for obtaining beneficial or desired therapeutic effects, which may be established clinically by means of physiological, metabolic or biochemical parameters. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization of symptoms, delay or slowing of progression, amelioration or palliation of a condition or a symptom, and remission (whether partial or total). The term “palliation” encompasses herein undesirable manifestations of a physiological condition or a symptom which are lessened and/or a progression which is slowed or lengthened, as compared to the same but untreated condition.
- Still further, in certain embodiments, preparations and methods of the invention involve combination therapies, administered simultaneously or in succession with other methods and drugs (also therapeutic agents).
- Therapeutic agents that are relevant can be, although not limited to General Drug Categories, classified by the FDA according to their clinical effects and applicability to common human disorders: analgesics, antacids, antianxiety drugs, antiarrhythmics, antibacterials, antibiotics, antimicotics, anticoagulants and thrombolytics, anticonvulsants, antidepressants, antidiarrheals, antiemetics, antifungals, antihistamines, antihypertensives, anti-inflammatories, antineoplastics, antipsychotics, antipyretics, antivirals, barbiturates, beta-blockers, bronchodilators, cold cures, cholesterol lowering drugs, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, expectorant, hormones, hypoglycemics, immune-suppressive, laxatives, muscle relaxants, sedatives, sex hormones, sleeping drugs, tranquilizer and vitamin supplements, such as omega fatty acids, omega-3-fatty acids, EPA, DHA, ALA.
- In terms of therapeutic effects, an improvement as a result of treatment is identified if there is at least about 5% improvement, or 10% improvement, or at least 25%, or at least 50%, or at least 75%, or at least 100% improvement or more. An improvement herein can be interpreted in the sense of individual improvement as well as population improvement.
- The term “about” in all its appearances in the text denotes up to a ±10% deviation from the specified values and/or ranges, more specifically, up to ±1%, ±2%, ±3%, ±4%, ±5%, ±6%, ±7%, ±8%, ±9% or ±10% deviation therefrom.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It should be understood that any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. Some embodiments of the invention will be now described by way of examples with reference to accompanying figures.
- Thus, in summary—the invention provides, inter alia, the following:
- A water-dispersible powder comprising lipophilic nanospheres (submicron nanodroplets) containing a cannabinoid material and further comprising:
-
- at least one cryoprotectant selected from sucrose, trehalose, mannitol,
- at least one surfactant selected from ammonium glycyrrhizinate, pluronic F-127, pluronic F68, and
- optionally at least one carbohydrate selected from maltodextrin and carboxymethyl cellulose (CMC).
- In some embodiments, upon dispersion in water the powder produces nanodroplets with a substantially same average size.
- In some embodiments, the powder comprises sucrose, trehalose or mannitol and further comprising ammonium glycyrrhizinate and maltodextrin.
- In some embodiments, the powder comprises pluronic F-127 or pluronic F68, and further comprising sucrose and maltodextrin.
- In some embodiments, the powder comprises sucrose, ammonium glycyrrhizinate, maltodextrin and CMC.
- Other embodiments are recited hereinabove.
- In some embodiments, wherein the cannabinoid material comprises at least one synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- In some embodiments, the powder wherein the concentration of a surfactant is in the range of about 3-10% (w/w).
- In some embodiments, wherein the fraction of lipophilic nanodroplets is in the range of about 10-50% (w/w).
- In some embodiments, the powder is in a solidified or compressed solid form.
- The invention further provides a method for producing a water-dispersible powder, the method comprising converting to a powder by lyophilization an emulsion of an oil phase and an aqueous phase; the aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein, the oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof.
- In some embodiments, the method comprises:
-
- (i) preparing an initial emulsion by an oil phase into an aqueous phase; the aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein, the oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof,
- (ii) preparing a final emulsion by sonicating or homogenizing the initial emulsion; and
- (iii) converting the nanoemulsion to powder by lyophilization.
- In some embodiments, the method comprises:
-
- (i) preparing an aqueous phase comprising a cryoprotectant, a surfactant and optionally at least one carbohydrate, as defined herein,
- (ii) preparing an oil phase comprising a synthetic or a natural cannabinoid, a cannabis extract or a fraction thereof,
- (iii) preparing an initial emulsion by adding the oil phase into the aqueous phase during homogenization,
- (iv) preparing a final emulsion by sonicating or homogenizing the initial emulsion, and
- (v) converting the nanoemulsion to powder by lyophilization.
- In some embodiments, the nanoemulsion obtained in (iv) and the powder in (v), upon dispersion in water, produce nanospheres (nanodroplets) with a substantially identical average size.
- In some embodiments, the step of preparing the initial emulsion in (iii) further comprises high pressure homogenization for at least 1 to 10 runs or more.
- In some embodiments, the step of preparing the final emulsion in (iv) involves sonication for at least about 5-60 min.
- In some embodiments, the step of preparing the aqueous phase in (i) is carried out at room temperature.
- Further provided is a water-dispersible powder produced by a method of the invention.
- In some embodiments, the oil phase is in the range of about 10-50% (w/w).
- In some embodiments, the powder is in a solidified or compressed solid form.
- 0.25 gr ammonium glycyrrhizinate, (Sigma, 50531-5OG, cas: 53956-04-0), 2 gr Maltodextrin, (Sigma, 419699-50OG, cas: 9050-36-6), 2 gr sucrose, (Sigma, 59378-500G, cas: 57-50-1) and 14.3 gr triple distilled water (TDW) were mixed using a magnetic stirrer for 10 min at 35-40° C. until a complete dissolution and acquisition of an aqueous solution.
- 0.5 gr olive oil (commercial) was added to the solution of Stage I. Stage III Initial emulsion 0.5 gr of the olive oil/hemp oil was added to the aqueous phase drop ways in the course of homogenization by high shear homogenizer (ULTRA TORAX, IKA T25 digital, 10,200 rpm) for at least 5 min.
- The homogenized emulsion was sonicated in an ice bath (Ultrasonic cell crusher SKL-750, SYCLON, Probe 1.1 cm diameter as probe no. 10) for 10 min under the conditions of Amplitude: 90%, ON: 2 sec, OFF: 1 sec.
-
-
- 1. The nanoemulsion was transferred to a glass vail and the vail was frozen in a bath of liquid nitrogen for 5 minutes.
- 2. The vail was lyophilized at absolute pressure of <1 mbar for 48 h (Labconco freezone 2.5).
- The resultant powder, being a dry fine powder, was stored in closed glass vials.
- The powder was dispersed (0.1-1 wt %) in TDW. The samples were vortexed for 1-2 min to obtain a translucent emulsion.
- Droplet size: Droplet size of the O/W nanoemulsion was estimated at Z Average: 160 nm peak 1: 99 nm, 56%; peak 2: 281 nm, 44%, polydispersity index (Pdi): 0.191 (measured by dynamic light scattering (DLS); and after dispersion in water at Z Average: 173 nm peak 1: 94 nm, 43.3%; peak 2: 274 nm, 53.6%; peak 3: 4943 nm, 3.1%, Pdi: 0.227.
Stability: The powder containing 10.5% w/w of olive remained stable after at least 9 weeks of observation. - Compositions of the nanoemulsion and powder are presented in Tables 2 and 3.
-
TABLE 2 Composition of the nanoemulsion Ingredients % w/w olive oil 2.6246 Maltodextrin 10.4986 Sucrose 10.4986 Ammonium 1.3123 glycyrrhizinate TDW 75.065 -
TABLE 3 Composition of the oil powder Ingredients % w/w olive oil 10.5263 Maltodextrin 42.10526 Sucrose 42.10526 Ammonium 5.26315 glycyrrhizinate - Characterization: Cryo TEM analysis was conducted for the emulsion (10% in water) and for the dispersed powder (1% in water). The images are presented in
FIG. 1 . - The same experiments were conducted using 10% hemp oil out of 90% olive oil fraction, and 100% oil fraction of hemp oil. Sonication, lyophilization and dispersion conditions were as in Example 1. Droplet size of the O/W nanoemulsion was estimated at the following values:
- For the 10% hemp oil: Z Average: 173.6 nm peak 1: 192.9 nm, 100%, Pdi: 0.213; and after dispersion in water at Z Average: 191.6 nm peak 1: 194 nm, 100%, Pdi: 0.290.
For the 100% hemp oil: Z Average: 163.3 nm peak 1: 184.7 nm, 93.2%; peak 2: 4956 nm, 1.1%; peak 3: 38 nm, 5.7%, Pdi: 0.169; and after dispersion in water at Z Average: 166 nm peak 1: 99.30 nm, 55.4%; peak 2: 287.3 nm, 44.6%, Pdi: 0.221. - The same experiments were conducted using trehalose or mannitol instead of sucrose as cryoprotectant, under the same conditions in terms of sonication, lyophilization and dispersion as in Example 1. Droplet size of the O/W nanoemulsion was estimated at the following values:
- For trehalose: Z Average: 157.5 nm peak 1: 169.3 nm, 100%; polydispersity index (Pdi): 0.191; and after dispersion in water at Z Average: 171.6 nm peak 1: 163.6 nm, 98.9%; peak 2: 4703 nm, 1.1%, Pdi: 0.276.
For mannitol: Z Average: 142.4 nm peak 1: 145.4 nm, 94%; peak 2: 30 nm, 6%; polydispersity index (Pdi): 0.169; and after dispersion in water at Z Average: 167.7 nm peak 1: 180.9 nm, 89.2%; peak 2: 36 nm, 10.8%; Pdi: 0.212. - The same experiments were conducted with pluronic F-127 and pluronic F-68, (Polyoxyethylene-polyoxypropylene block copolymer) instead of ammonium glycyrrhizinate as surfactant under the same conditions as in Example 1. Droplet size of the O/W nanoemulsion was estimated at the following values:
- For pluronic F-127: Z Average: 149.7 nm peak 1: 141.1 nm, 100%, Pdi: 0.183; and after dispersion in water at Z Average: 199.8 nm peak 1: 218 nm, 100%, Pdi: 0.149.
For pluronic F-68: Z Average: 145.7 nm peak 1: 154.8 nm, 100%, Pdi: 0.161; and after dispersion in water at Z Average: 241.7 nm peak 1: 259.4 nm, 99.1%; peak 2: 5362 nm, 0.9%, Pdi: 0.263. - The nanoemulsions were prepared with different surfactant concentrations in the range of 3.15-7.7% w/w in the powder. For example, 0.15-0.35 gr pluronic F-127, 1.9-2.1 gr Maltodextrin, 2 gr sucrose, and 14.3 gr TDW were mixed using a magnetic stirrer for 10 min at 35-40° C. until a complete dissolution, all other components, and homogenization and sonication parameters remained the same. The effect on the droplet (particle) size is demonstrated in
FIG. 2 . - The nanoemulsions were prepared with 0.25 gr ammonium glycyrrhizinate as surfactant. The emulsions were sonicated as in stage IV, Example 1, for the duration of 5 to 60 min, all other components and homogenization parameters remained the same. The effect on the droplet (particle) size is demonstrated in
FIG. 3 . - The following formulation was prepared: 0.5 gr Pluronic F127, 4 gr Maltodextrin, 4 gr sucrose, and 28.6 gr TDW were mixed using a magnetic stirrer for 10 min at RT until a complete dissolution. In the next stage, 1 gr of the hemp oil was added to the aqueous phase drop ways during homogenization by high shear homogenizer as in stage III, Example 1, this stage was repeated 4 times to obtain a sufficient amount of product for the homogenization step.
- The final emulsion was prepared by HP homogenizer wherein 100 gr of the obtained emulsions were subjected to homogenization for 1 to 6 runs (cycles). The results are demonstrated in
FIG. 4 . Droplet size of the O/W nanoemulsion was estimated at the following values: - For 1 homogenization run: Z Average: 182 nm peak 1: 198 nm, 97.5%; peak 2: 4976 nm, 2.5%, Pdi: 0.151.
For 6 homogenization runs: Z Average: 157 nm peak 1: 167 nm, 100%, Pdi: 0.122. - The lyophilization and dispersion steps were as in stage V-VI, Example 1. Droplet size after dispersion in water was estimated at Z Average: 210 nm peak 1: 2064 nm, 100%, Pdi: 0.235.
- The following formulations were prepared: 0.3 gr ammonium glycyrrhizinate, 1.95 gr Maltodextrin, 2 gr sucrose, and 14.3 gr TDW were mixed as in Example 1. In the next stage, 1-4.25 gr of hemp oil (19-50% oil in powder) was added to the aqueous phase drop ways during homogenization as in stage III and sonicated as in stage IV, Example 1. The results are demonstrated in
FIG. 5 . - A high load formulation (50% hemp oil) was prepared as follows: 2.1 gr ammonium glycyrrhizinate, 13.65 gr Maltodextrin, 14 gr sucrose, and 100.1 gr TDW were mixed as in Example 8. In the next stage, 29.75 gr of hemp oil (50% oil in the powder) was added to the aqueous phase drop ways during homogenization by high shear homogenizer as in Example 8. The final emulsion was prepared by HP homogenizer as in Example 7. Droplet size of the O/W nanoemulsion was estimated at the following values:
- For 6 homogenization runs: Z Average: 182 nm peak 1: 107 nm, 33%, peak 2: 308 nm, 67%, Pdi: 0.177.
For 10 homogenization runs: Z Average: 176 nm peak 1: 202 nm, 98, peak 2: 4956 nm, 2%, Pdi: 0.146.
For 15 homogenization runs: Z Average: 175 nm peak 1: 201 nm, 100%, Pdi: 0.137. - Droplet size after dispersion in water was estimated at Z Average: 181 nm, peak 1: 114 nm, 41%, peak 2: 303 nm, 53%, peak 3: 1763 nm, 6%, Pdi: 0.193.
- The following formulation was prepared: 0.3 gr ammonium glycyrrhizinate, 1.95 gr Maltodextrin, 2 gr sucrose, 0.085 gr CMC, (Sigma, ultra-low viscosity, 36038-4, cas: 9004-32-4), and 14.3 gr TDW were mixed for 10 min at RT until a complete dissolution and acquisition of an aqueous solution. In the next step, 4.165 gr of hemp oil was added to the aqueous phase, homogenized drop ways during homogenization by high shear homogenizer as in Example 1 for the duration of 10 min, followed by sonication as in Example 7.
- Droplets size of the O/W nanoemulsion was estimated at Z Average: 145.7 nm peak 1: 30 nm, 4%; peak 2: 100 nm, 49%; peak 3: 307 nm, 47%, Pdi: 0.161; and after dispersion in water at Z Average: 190 nm, peak 1: 180 nm, 94%, peak 2: 963 nm, 3%, peak 3: 5151 nm, 3%, Pdi: 0.322.
- It should be noted that among the various selected agents used for the preparation of the various formulations of the invention so far, cyclodextrin was proven to be incompatible in terms of a complete dissolution to obtain the aqueous phase as in Example 1,
Stage 1. - The presently described tablets were prepared from the powder obtained in Example 7 using a tablets compresser (PIKE Technologies, CrushIR TM, under 9-9.5 tons), certain illustrations thereof are provided in
FIG. 6 . Each 300 mg or 650 mg tablet contained the hemp oil powder formulation of the invention (HOP), and additional functional agents from state of the art in respective concentrations. One optional application of such tables is for sublingual administration. Certain examples of the produced tablets are given below: -
- Tablet 1: 300/650 mg of 10.5% hemp oil powder (HOP)
- Tablet 2: 294 mg HOP+6 mg Magnesium stearate (MS)
- Tablet 3: 294 mg HOP+6 mg Glycine (G)
- Tablet 4: 294 mg HOP+6 mg PVP (40,000)
- Tablet 5: 288 mg HOP+6 mg MS+6 mg G
- Tablet 6: 288 mg HOP+6 mg G+6 mg PVP
- Tablet 7: 288 mg HOP+6 mg PVP+6 mg MS
- Tablet 8: 282 mg HOP+6 mg MS+6 mg G+6 mg PVP
- Disintegration tendency of the above types of tablets is shown in Table 4. Tablets were immersed in TDW at 37° C., under gentle shaking. Results of visual inspection are presented (CD—complete dissolution, TNT thin tablet, TKT—thick tablet).
-
TABLE 4 Disintegration tendency of various tablet preparations Time/Tablet no, 1 2 3 4 5 6 7 8 12 min TNT TNT TNT TNT TKT almost TKT TKT CD 15 min almost TNT CD almost TKT almost TKT TKT CD CD CD 18 min almost almost CD CD TKT CD TKT TKT CD CD 20 min almost almost CD CD TKT CD almost TKT CD CD CD 22 min CD CD CD CD almost CD almost TKT CD CD 24 min CD CD CD CD CD CD CD almost CD 25 min CD CD CD CD CD CD CD CD - The above findings suggest that MS and combination of MS and PVP can inhibit the disintegration of a tablet.
- After disintegration, the tablets were subjected to DLS measurements in order to evaluate droplets size, which revealed that for all types of tables the droplets size were still in the nanometric range, e.g., 250-290 nm.
- Disintegration Profiles of the HOP Tables Vs. Centrum Junior Tables
- Disintegration profiles of the tablets were further studied comparing HOP table No. 8 (see Example 11) and Centrum Junior sublingual tablet. Both types of tablets, each 300 mg, were immersed in TDW 37° C. under vigorous shaking (see
FIG. 7 ). Tablets were removed from water every 2 min, excess liquid was absorbed into paper, and tablets were weighed. - After 6 min the HOP tablet became very gentle and sensitive to touch, and it was left in water until complete disintegration. The disintegration profile (tablet weight vs. dissolution time) of the HOP tablet was essentially similar to the Centrum tablets (see
FIG. 8 ). - In order to evaluate the effect of different pH on the obtained droplets size, three different redispersed emulsions were prepared as follows: 15 mg of cannabis oil powder, (contains 30% oil in powder), were dispersed, by a 20 second of vortex, in 3 ml of aqueous medium to obtain emulsion concentration of 0.5% w/w of the powder in the water.
- The pH of the first aqueous medium was 1.2, mimicking stomach conditions. The pH of the second aqueous medium, distilled water, was 5.5 and the pH of the third aqueous medium was 6.8, mimicking intestines conditions.
- After redispersion, one droplet of the dispersed emulsion was mixed with 2 ml of the certain aqueous medium and the sample was measured by DLS zetasizer equipment at TO and after 24 h. Each sample was prepared in duplicate and measured in 3 cycles for each sample.
- The average results are presented in Table 5:
-
TABLE 5 Size of nanodroplets under various pH values T zero avg pdi peak1 % peak2 % peak3 % TDW PH 320 0.343 307 75.6 818 21.8 4972 2.6 5.5 PH 1.2 307 0.326 467 78.8 113 18.2 5319 3 PH 6.8 376 0.423 460 90 67 3.3 5255 6.7 T 24 h Avg pdi peak1 % peak2 % peak3 % TDW PH 284 0.305 257 87.8 4746 12.2 5.5 PH 1.2 312 0.376 440 72.7 121 24.3 5392 3 PH 6.8 347 0.338 419 79.1 106 19.9 5473 1 - As may be understood from Table 5, the effect of the pH on the droplets size was not significant and also the differences between TO and after 24 h were negligible.
- Formulation comprising Cannabis oil, 19% oil in powder. The final powder contains 8 mg THC/gr and 2 mg CBD/gr.
- The following exemplary formulation was prepared: 1.44 gr Pluronic F127, 8.5 gr Maltodextrin, 9.6 gr sucrose, one stevia tablet, weigh 82 mg which contains 12 mg of stevia dissolved in 2 gr of worm water and 67 gr TDW were mixed using a magnetic stirrer for 10 min at RT until a complete dissolution. In the next stage, 4.56 gr of the cannabis oil were added to the aqueous phase drop ways during homogenization by high shear homogenizer as in stage III, Example 1. The final emulsion was prepared by HP homogenizer as in Example 7 but with microfluidizer, M110P technology, equipment. Droplet size of the O/W nanoemulsion was estimated at the following values:
- For 1 homogenization run: Z Average: 157 nm peak 1: 161 nm, 100%; Pdi: 0.123.
For 2 homogenization runs: Z Average: 158 nm peak 1: 163 nm, 100%; Pdi: 0.103.
For 3 homogenization runs: Z Average: 147 nm peak 1: 148 nm, 100%; Pdi: 0.108.
For 4 homogenization runs: Z Average: 142 nm peak 1: 143 nm, 100%; Pdi: 0.119.
For 5 homogenization runs: Z Average: 141 nm peak 1: 142 nm, 100%; Pdi: 0.112. - The lyophilization step was as in stage V, Example 1. Droplet size after dispersion in water was estimated at Z Average: 224 nm peak 1: 233 nm, 100%, Pdi: 0.194.
Claims (19)
1. A water-dispersible powder comprising lipophilic nanospheres having an averaged size between 50 and 900 nm as measured by dynamic light scattering (DLS), the nanospheres comprising a cannabinoid material and having an adsorbed layer comprising at least one solid surfactant, wherein the at least one solid surfactant is selected from the group consisting of Poloxamer 407, Poloxamer 188, and ammonium glycyrrhizinate;
the powder further comprising at least one solid cryoprotectant selected from the group consisting of sucrose, trehalose and mannitol, and optionally at least one solid carbohydrate selected from the group consisting of maltodextrin and carboxymethyl cellulose (CMC);
wherein the nanospheres' structure and size is substantially maintained upon dissolution in a water containing environment.
2. The powder according to claim 1 , comprising at least one solid carbohydrate.
3-33. (canceled)
34. The powder according to claim 1 , wherein said cannabinoid material is a synthetic or natural cannabinoid is-selected from tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), a derivative, a precursor and an acid-form thereof.
35-37. (canceled)
38. The powder according to claim 1 , adapted for enteral, parenteral, subligual, topical or transdermal administrations.
39. A method for producing a water-dispersible powder of claim 1 , the method comprising converting a nanoemulsion to a powder by lyophilization, the nanoemulsion being of an oil phase and an aqueous phase; the aqueous phase comprising a solid cryoprotectant, a solid surfactant and optionally at least one solid carbohydrate, and the oil phase comprising a cannabinoid material.
40. The method according to claim 39 , the method comprising:
(i) preparing an initial nanoemulsion by adding an oil phase into an aqueous phase; the aqueous phase comprising a solid cryoprotectant, a solid surfactant and optionally at least one solid carbohydrate, the oil phase comprising a cannabinoid material,
(ii) preparing a final nanoemulsion by sonicating or homogenizing the initial nanoemulsion;
(iii) converting the final nanoemulsion to a powder by lyophilization.
41. The method according to claim 40 , comprising:
(i) preparing an aqueous phase comprising a solid cryoprotectant, a solid surfactant and optionally at least one solid carbohydrate,
(ii) preparing an oil phase comprising a cannabinoid material,
(iii) preparing an initial nanoemulsion by adding the oil phase into the aqueous phase during homogenization,
(iv) preparing a final nanoemulsion by sonicating or homogenizing the initial nanoemulsion, and
(v) converting the final nanoemulsion to a powder by lyophilization.
42-48. (canceled)
49. A pharmaceutical composition comprising the water-dispersible powder of claim 1 , optionally further comprising a pharmaceutically acceptable carrier or excipient.
50-55. (canceled)
56. A dosage form for oral or sublingual administration, the dosage form comprising a water-dispersible powder of claim 1 .
57-63. (canceled)
64. A method of treating a disease or a medical condition related to beneficial effects of cannabinoids or cannabis, the method comprising administering to a subject a therapeutically effective amount of a powder of claim 1 .
65-66. (canceled)
67. A nanoemulsion comprising lipophilic nanodroplets containing a cannabinoid material and having an averaged size between 50 and 900 nm as measured by dynamic light scattering (DLS); at least one soluble solid surfactant selected from the group consisting of Poloxamer 407, Poloxamer 188, and ammonium glycyrrhizinate; at least one soluble solid cryoprotectant selected from the group consisting of sucrose, trehalose and mannitol, and optionally containing maltodextrin and/or carboxymethyl cellulose (CMC).
68. The powder according to claim 1 , wherein Poloxamer 407 has a structure in the range of HO[CH2CH2O]95-105[CH2CH(CH3)O]54-60[CH2CH2O]95-105H. and Poloxamer 188 has a structure in the range of [CH2CH2O]75-85[CH2CH(CH3)O]25-30[CH2CH2O]75-85H.
69. The powder according to claim 68 , wherein Poloxamer 407 has an average molecular weight of 10000 to 14600 g/mol and Poloxamer 188 has an average molecular weight of 7680 to 9510 g/mol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/209,954 US20230321031A1 (en) | 2018-08-13 | 2023-06-14 | Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL261132A IL261132A (en) | 2018-08-13 | 2018-08-13 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
IL261132 | 2018-08-13 | ||
PCT/IL2019/050268 WO2020035850A1 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
US202016958341A | 2020-06-26 | 2020-06-26 | |
US18/209,954 US20230321031A1 (en) | 2018-08-13 | 2023-06-14 | Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2019/050268 Continuation WO2020035850A1 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
US16/958,341 Continuation US11712430B2 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsification, methods of producing and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230321031A1 true US20230321031A1 (en) | 2023-10-12 |
Family
ID=63998426
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/958,341 Active US11712430B2 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsification, methods of producing and uses thereof |
US18/209,954 Pending US20230321031A1 (en) | 2018-08-13 | 2023-06-14 | Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/958,341 Active US11712430B2 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsification, methods of producing and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (2) | US11712430B2 (en) |
EP (1) | EP3716946A1 (en) |
JP (1) | JP2021535935A (en) |
CN (1) | CN113473965A (en) |
AU (1) | AU2019322212B2 (en) |
BR (1) | BR112021009869A2 (en) |
CA (1) | CA3086887A1 (en) |
CO (1) | CO2021007647A2 (en) |
IL (2) | IL261132A (en) |
WO (1) | WO2020035850A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020220141A1 (en) * | 2019-05-02 | 2020-11-05 | Betterlife Pharma Inc. | Cannabinoid stock transdermal formulations |
US10780075B1 (en) | 2019-07-31 | 2020-09-22 | Etain IP, LLC | Water soluble cannabis composition |
CA3149966A1 (en) * | 2019-08-12 | 2021-02-18 | Tenshi Kaizen Private Limited | Cannabidiol orally disintegrating tablets |
IL295386A (en) * | 2020-07-29 | 2022-10-01 | Karnak Tech Llc | Improved formulations of lipophilic subtances for cosmetic uses |
CN115843242A (en) | 2020-07-29 | 2023-03-24 | 卡纳克科技有限责任公司 | Oral compositions of lipophilic dietary supplements, nutraceuticals and beneficial edible oils |
WO2022024127A1 (en) | 2020-07-29 | 2022-02-03 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
EP4196112A1 (en) * | 2020-08-14 | 2023-06-21 | Capheads LLC | Dosing capsule made from cannabis-derived resin and methods of making the same |
CA3114085A1 (en) * | 2021-04-05 | 2022-10-05 | MEC11S Inc. | Composition comprising cannabis extracts and method of manufacturing same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011210352A1 (en) * | 2010-01-26 | 2012-08-09 | Radikal Therapeutics Inc. | Compositions and methods for prevention and treatment of pulmonary hypertension |
US8629177B2 (en) * | 2010-08-24 | 2014-01-14 | Aphios Corporation | Nanoencapsulated delta-9-tetrahydrocannabinol |
ES2739194T3 (en) | 2012-01-19 | 2020-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulation and method to increase oral bioavailability of drugs |
AU2013263292B2 (en) | 2012-05-16 | 2018-03-08 | Maninder SANDHU | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
WO2015171445A1 (en) | 2014-05-06 | 2015-11-12 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
US20160058866A1 (en) | 2014-09-02 | 2016-03-03 | Ronald D. Sekura | Alternative solutions for the administration of cannabis derived botanical products |
US9629886B2 (en) | 2015-02-24 | 2017-04-25 | Ers Holdings, Llc | Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil |
AU2016231788A1 (en) | 2015-03-19 | 2017-10-12 | One World Cannabis Ltd | Preparations of cannabis emulsions and methods thereof |
EP3368014B1 (en) * | 2015-10-26 | 2023-10-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Novel cannabinoid formulations |
JP2019511580A (en) | 2016-04-15 | 2019-04-25 | エスアールイー ウェルネス インク.Sre Wellness Inc. | Method of making cannabis oil hydrophilic using an emulsifier and related cannabinoid compositions |
-
2018
- 2018-08-13 IL IL261132A patent/IL261132A/en unknown
-
2019
- 2019-03-11 US US16/958,341 patent/US11712430B2/en active Active
- 2019-03-11 AU AU2019322212A patent/AU2019322212B2/en active Active
- 2019-03-11 WO PCT/IL2019/050268 patent/WO2020035850A1/en unknown
- 2019-03-11 JP JP2021547984A patent/JP2021535935A/en active Pending
- 2019-03-11 BR BR112021009869A patent/BR112021009869A2/en not_active Application Discontinuation
- 2019-03-11 CN CN201980067584.5A patent/CN113473965A/en active Pending
- 2019-03-11 EP EP19714807.5A patent/EP3716946A1/en active Pending
- 2019-03-11 CA CA3086887A patent/CA3086887A1/en active Pending
-
2020
- 2020-06-17 IL IL275430A patent/IL275430A/en unknown
-
2021
- 2021-06-10 CO CONC2021/0007647A patent/CO2021007647A2/en unknown
-
2023
- 2023-06-14 US US18/209,954 patent/US20230321031A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210059975A1 (en) | 2021-03-04 |
AU2019322212A1 (en) | 2021-04-08 |
IL261132A (en) | 2018-11-04 |
CO2021007647A2 (en) | 2021-08-30 |
WO2020035850A1 (en) | 2020-02-20 |
AU2019322212B2 (en) | 2022-09-29 |
JP2021535935A (en) | 2021-12-23 |
CA3086887A1 (en) | 2020-02-20 |
US11712430B2 (en) | 2023-08-01 |
BR112021009869A2 (en) | 2022-05-17 |
EP3716946A1 (en) | 2020-10-07 |
IL275430A (en) | 2020-08-31 |
CN113473965A (en) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230321031A1 (en) | Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof | |
US11654111B2 (en) | Oral solid cannabinoid formulations, methods for producing and using thereof | |
US11590230B2 (en) | Compositions of therapeutic substances, methods and uses thereof | |
US10166185B2 (en) | Excipient and oral solid dosage forms for oily drugs | |
WO2021195173A1 (en) | Solid cannabinoid formulation for oral administration | |
CN112915121A (en) | Cannabinoid nano micelle preparation and preparation method thereof | |
US20200215024A1 (en) | Cannabinoid formulations for treating alcohol hangover | |
US20220193008A1 (en) | Bioaccessibile compositions of lipophilic compounds and process thereof | |
US20180263954A1 (en) | Sustained Release Cannabinoid Formulations | |
US20230270678A1 (en) | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives | |
Alshawwa et al. | Solid lipid Lyo-Nanosuspension: A promising stabilized oral delivery system for the antihyperglycemic extract of mistletoe Plicosepalus acacia | |
WO2022141665A1 (en) | Water-soluble cannabinoid formulation and preparation method therefor | |
CA3005885A1 (en) | Sustained release cannabinoid pellets | |
WO2022014601A1 (en) | Film-coated tablets | |
Yin et al. | Phytoconstituent-derived nano-medicines/vesicles providing a promising dawn for inflammatory bowel disease | |
WO2023238122A1 (en) | Formulations and oral dosage forms of lipophilic agents | |
WO2016201119A1 (en) | Excipient and oral solid dosage forms for oily drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |